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Introduction 
One of the earliest known written reports on senile dementia is attributed to 
Pythagoras in the 7'h centmy B.C, who described old age as a period of decline 
and decay of the human body and regression of mental capacities.! In 1907, it 
was Alois Alzheimer who first describcd the finding of neurofibrillmy tangles in 
a middle-aged woman with a clinically unusual dementia.2-4 He considered that 
a rare condition. Nowadays Alzheimer's disease is regarded the most frequent 
cause of senile dementia, with prevalencc ranging from less than I % for those 
aged 55-64 years to over 25% for those aged 85 years and over.5 
Although numerous studies have been done to identify risk factors for 
dementia and Alzheimer's disease, the actiology is still largely unknown. Over 
the last decade, epidemiological evidence has mounted that vascular factors and 
indicators of vascular disease are associated with the risk of Alzheimer's 
disease.6-8 However, most evidence came from cross-sectional studies and 
studies with a short follow-up9-11 Since the underlying neuropathology may 
start long before dementia can be clinically recognised, we need studies with a 
longcr follow-up to unravel cause and consequence in the association between 
vascular factors and dementia. 
The aim of the research described in tltis thesis was to further quantify the 
role of vascular factors in the aetiology of dementia and Alzheimer's disease and 
to identify possible underlying mechanisms. We studied the association between 
vascular risk factors and dementia in the Rotterdam Study, a large population-
based cohort study on 7,983 persons of 55 years and older living in a suburb of 
Rotterdam, the Netherlands, that started in 1990. Since the start of the study we 
tried to identify all new cases of dementia, and distinguish them according to 
subtype (Alzheimer's disease and vascular dementia) (chapter 2). 
It has been suggested that hypertension is an important risk factor for 
vascular dementia.!2 Also, a recent trial suggested that in elderly people 
treatment of isolated systolic hypertension reduced the risk of dementia. 13 We 
explored the possible association between blood pressure level, antihypertensive 
treatment and dementia, Alzheimer's disease and vascular dementia (chapter 3). 
3 
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Most vascular risk factors are not stable over time and change in vascular risk 
factor level may be more important than actual level. Therefore, we studied both 
the short-term (chapter 3.1) and long-term effects of elevated blood pressure 
(chapter 3.2). In addition we examined the association betwcen change in blood 
pressure level and risk of dementia (chapter 3.2). 
In an earlier repOlt from the Rotterdam Study we found that the frequencies 
of dementia, Alzheimer's disease, and vascular dementia increased with the 
degree of atherosclerosis. These findings were based on prevalent dementia 
cases. Because cross-sectional studies are prone to selection- and survival bias, 
we now investigated tllis association prospectively based on incident cases of 
dementia (chapter 4.1). We investigated cerebral functional status as assessed 
with Transcranial Doppler sonography in relation to occurrence of dementia and 
cognitive dysfunction (chapter 4.2). Light-to-moderate alcohol intake has been 
reported to be associated with a lower risk of atherosclerosis. Since 
atherosclerosis has bcen linked to a higher risk of dementia, we hypothesised 
that moderate alcohol consumption might be associated with a reduced risk of 
dementia. We therefore evaluated the relation between alcohol intake and risk of 
dementia and whether this association was dependent on specific alcoholic 
bcverages (chapter 4.3). 
Current knowledge on the prognosis of dementia and Alzheimer's disease is 
limited. To evaluate the effect of interventions on the risk of institutionalisation 
and mortality among patients with Alzheimer in different stages of the disease, it 
is important to have detailed information on the natural progression of 
Alzheimer's disease. We developed a prognostic risk function to predict rate of 
cognitive decline, institutionalisation, and death in Alzheimer's disease based on 
characteristics of Alzheimer patients derived from the Rotterdam Study (chapter 
5). 
In chapter 6, the main results of the studies described in tltis thesis are 
reviewed and discussed in the light of other studies and current insights in the 
association between vascular factors and Alzheimer's disease, and suggestions 
for future research are given. 
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2 
FREQUENCY OF 
DEMENTIA 

2.1 
Incidence of dementia 
Abstract 
Objective: To estimate gender specific incidence rates of dementia and its 
sub01Jes in the general population 
Dcsign: Population-based prospective cohort study 
Setting: Ommoorel, a suburb of Rofferdam, the Netherlands 
SUbjects: 7,046 non-demented participants of the Rofferdam study aged 55 
years and older. 
Main outcomc measurement: Incident dementia and subOpes of dementia. 
Results: In 40,441 person-years offollow-up (mean 5.7 years) we identified 395 
new cases of dementia, yielding all overall incidence of 9.8 per 1,000 person-
years, in those 55 years and over. Incidence rallgedji'om 0.4 per 1,000 person-
years at age 55-59 years to 74.1 per 1,000 person-years at age 95 years and 
older. Alzheimer~~ disease was the most ji'equent subOpe of dementia (293 
cases; 7.2 per 1,000 person-year,). Vascular demelltia was diagnosed in 57 
participants (1.5 per 1,000 person-years). Overall, dementia illcidence was 
similar for men alld women (rate ratio women versus mell: 1.00, 95% CI: 0.80-
1.24). However, after 90 years of age dementia incidellce dec/illed ill men but 
1I0t in women (rate ratio 2.61,95% CI: 1.04-6.56), in particularfor Alzheimer's 
disease (rate ratio 5.79, 95% CI: 1.40-23.90). The overall incidence of vascular 
dementia was lower in womenthall in men (rate ratio 0.57, 95% CI: 0.34-0.97). 
Conclusions: This large population-based study suggests 110 gender differences 
in the incidence of dementia up to high age. Afier 90 years of age the incidence 
of Alzheimer's disease is higher for women than for men. The incidence of 
vascular dementia is higherfor men than/or women in all age groups. 
9 
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Introduction 
Dementia is one of the major health problems in our ageing societies. Therefore, 
reliable estimates of the frequency of dementia are important. Incidence studies 
have repOited inconsistent results on the occurrence of dementia by gender. 
Some studies suggested a higher incidence rate in women than in men, 
especially after age 85,1-6 whereas other studies showed no gender difference.7-11 
As to Alzheimer's disease, dementia's major subtype, most studies repOited 
higher incidence rates for women than for men.2, 3, 8, 12 The discrepancies 
between the various studies may result from small sample size, particularly in 
the highest age range, use of different diagnostic criteria and differences in 
completeness of follow-up. 
We previously reported incidence data from the Rotterdam Study, a large 
Jlopulation-based Shldy conducted in the Netherlands, after a relatively short 
follow-up of on average two years. We now have more than 40,000 person years 
of follow-up and were able to investigate possible gender differences in 
incidence of dementia and its subtypes. 
Methods 
Study design 
The Rotterdam Shldy is a population-based prospective cohort Shldy among 
7,983 persons aged 55 years and older. l3 Baseline examinations took place 
between 1990 and 1993. Participants were interviewed at their homes and 
thereafter, during two sessions, examined at the research centre. Follow-up 
examinations took place in 1993-1994 (fIrst follow-up) and in 1997-1999 
(second follow-up). 
Study population 
The Shldy was conducted in Ommoord, a suburb of the city of Rotterdam, the 
Netherlands. At baseline, all inhabitants aged 55 years and older, including those 
living in institutions, were invited to participate. Of 10,275 eligible persons, 
7,983 agreed to take part in the Shldy, and 7,528 (94.3%) were screened and 
examined for dementia. 14 Of these, 474 persons were diagnosed with dementia. 
10 
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During follow-up, another 8 persons were considered demented at baseline in 
retrospect. Tltis resulted in a cohOit of7,046 participants at risk for dementia. 
Diagnosis of dementia 
For dementia screening and diagnosis during baseline and follow-up we adhered 
to a tlu'ee-step protocol. 15 Briefly, all participants were screened with a short test 
of cogttition (Mini Mental State Examination 16 and the Geriatric Mental State 
schedule, orgattic levelI7). Screen positives (persons scoring below 26 on the 
MMSE or more than 0 on the GMS) underwent further cognitive testing with the 
Cambridge examination for mental disorders of the elderly (CAMDEX), 18 whieh 
included an informant interview. Persons suspected of dementia were examined 
by a neurologist, underwent neuropsychological testing, and if possible a brain 
scan was made by magnetic resonance imaging. Of the participants suspected of 
dementia and whose dementia work-up was not complete, medical files were 
reviewed for additional diagnostic information. 
In addition to active dementia screening, we were alerted by the participants' 
general practitioners of interval cases of dementia or cognitive disturbances at a 
regular basis.15 Study physicians evaluated all reports of incident memOty 
problems or dementia. For non-respondents to the follow-up examination, 
informants and medical files were consulted in order to make a diagnosis of 
dementia. In addition, the Regional Institute for Outpatient Mental Health Care 
(RIAGG), which covers the entire study population, was consulted at a regular 
basis and all repOits were checked. This psycltiatric service can be consulted 
both directly and by referral for social and psychiatric problems. A geriatric 
section is responsible for nursing home or other dementia care facility 
indications. Surveillance of the population t1uough the general practitioner and 
RIAGG reports continued up to December 31, 1999. Of both the in-person-
screened individuals and those monitored through general practitioners and 
RlAGG, the study diagnosis of dementia was made according to established 
criteria (NINCDS-ADRDA, NINDS-AIREN, DSM-rrr-R) by a panel that 
reviewed all existing infol1nation. 15, 19·21 
Data analysis 
The age-specific incidence was obtained per 5-year age band by dividing the 
number of cases by the number of person-years, calculated by adding up each 
II 
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participant's contribution of follow-up time per age band. The follow-up period 
ended at thc second follow-up examination, at the date of invitation for second 
follow-up examination (for non-responders), at the age of onset of dementia or at 
dcath. The age of dementia onset was assumed to be the midpoint between the 
last known date whcn a person was not demented and the fn'st date of dementia 
diagnosis (either by in-person-screening or based on information from medical 
files). Incidence rates were estimated by age, gender, by dementia subtypc and 
by response category (fIrst and second follow-up). We calculated Poisson 
standard errors and 95 percent confIdence intervals. The difference in incidence 
between men and women was expressed as a rate ratio, which was calculated 
with proportional hazards regression analysis. To adjust most effIciently for age, 
we used age as the time scale in the proportional hazards models. 22 Ently time 
was defIned as age at study entry. Additionally, we performed a stratifIed 
analysis in age categories. 
Results 
In Table I characteristics of the study population are summarised. Of the total 
cohort (n = 7,046) at risk of developing dementia, 1,403 persons (19.9%) died 
during follow-up. For the second follow-up examination 48 persons who had 
moved to a nursing home far from the research centre were not invited and for 
those information was obtained through general practitioners. Follow up was 
virtually complete (99.6%) until December 31, 1999 (complete information 
during the fIrst follow-up period, 26 persons lost to follow-up during second 
follow-up period). 
Table 1. Characteristics ofparticipanls in the study on dementia incidence, the Rotterdam Stlld~. 
First foHow-up Second follow-up 
(1993-1994) (1997-1999) 
No. % % women No. % % women 
Screened in person 5,571 79.1 58.8 4,133 62.9 58.4 
Refusalofscreening-Iestt 999 14.2 68.9 1,484 22.6 68.3 
Died before follow-up examination 476 6.8 54.6 927 14.1 56.0 
Lost to follow-up 26 0.4 57.7 
Total cohort 7,046 100 59.9 6,570* 100 60.3 
"'Population alive after first follow-up (7,046 - 476) 
t Including 48 persons who were not invited because they moved to a nursing home far from the research 
centre 
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After 40,441 person-years of follow-up (mean follow-up period 5.7 years), 395 
new cases of dementia were identified, 215 in those examined in person and 180 
by general practitioner and mental health services monitoring. Alzheimer's 
disease was diagnosed in 293 (74 %); 216 of those had probable Alzheimer's 
disease and 77 had possible Alzheimer's disease, of whom there were 30 with 
co-existing cerebrovascular disease. Vascular dementia was diagnosed in 57 (14 
%) and other dementias in 37 (9 %). A subtype of dementia could not be 
determined in 8 persons (2 %). The proportion of subtypes differed between men 
and women: 64 % of male cases were diagnosed with Alzheimer's disease and 
21 % with vascular dementia; for female cases these proportions were 79 and 12, 
respectively. 
Table 2 and Figure la show the age- and gender-specific incidence rates of 
dementia. The incidence rate of dementia steeply increased with age from 0.4 
per 1,000 person-years at age 55-59 years to 74.1 per 1,000 person-years at age 
95 and older. The age-specific incidence rates were similar for men and women 
up to 90 years of age. However, after this age the incidence rates for women 
continued to rise, whereas for men the incidence rates dropped. 
[20 All dementia 
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Figure la. Age- and gender-specific incidence of all dementia in the Rotterdam 
Study, 1990-1999. 
Comparison of the incidence between the in-person screened and those whose 
information on dementia status came from informants and medical files revealed 
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Table 2. Age- and gender specific number of person-years at risk, dementia cases, and incidence rates (per 1,000 person-
years, witb 95% confidence interval (eI), in a Dutch general population, the Rotterdam Study, 1990-1999. 
Women Men Total EOQulation 
Age Person No. of Person No. of Person No. of 
category years at dementia Incidence years at dementia Incidence years at dementia Incidence 
(years) risk cases rate 95%CI risk cases rate 95%CI risk cases rate 95% CI 
55-59 1.578 0 0.0 0.0-5.1 1.122 0.9 0.1-6.3 2.701 0.4 0.1-2.6 
60-64 4.493 2 0.5 0.1-1.8 3.324 2 0.6 0.2-2.4 7.818 4 0.5 0.2-1.4 
65-69 4.855 7 1.4 0.7-3.0 3.875 8 2.1 1.0-4.1 8.731 15 1.7 1.0-2.9 
70-74 4.568 22 4.8 3.2-7.3 3.348 18 5.4 3.4-8.5 7.916 40 5.1 3.7-6.9 
75-79 3,832 55 14.4 11.0-18.7 2.361 40 16.9 12.4-23.1 6.192 95 15.3 12.6-18.8 
80-84 2.695 63 23.4 18.3-30.0 1.303 28 21.4 14.8-31.1 3,998 91 22.8 18.5-28.0 
85-89 1.600 71 44.4 35.2-56.0 510 23 45.1 30.0-67.9 2.110 94 44.5 36.4-54.5 
90-94 626 37 59.1 42.8-81.5 175 5 28.7 11.9-68.8 801 42 52.4 38.8-71.0 
;:: 95 144 13 90.2 52.4-155.4 31 0 0.0 0.0-255.9 175 13 74.1 43.1-127.7 
Total 24.392 270 ILl 8.9-10.8 16.049 125 7.8 6.5-9.3 40.441 395 9.8 8.9-10.8 
incidence a/dementia 
that there were no major differences in incidence up to age 85 years. Abovc age 
85 more demented persons were identified by personal examination than by 
evaluation of medical files (rate ratio 1.9, 95% CI: 1.2-3.0). The difference in 
incidence between men and women at velY high age could not be explained by 
differences in case finding. 
In Table 3 and Figure lb, and lc the age- and gender-specific incidence rates 
of Alzheimer's disease and vascular dementia are presented. The incidence of 
both Alzheimer's disease and vascular dementia incrcased with age, except for 
the oldest age groups in mcn where the incidence of Alzheimer's diseasc 
dcclined. 
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Table 3_ Age- and gender specific incidence rates of Alzheimer's disease and vascular dementia. 
Women Men Total population 
Alzheimer's disease Vascular Dementia Alzheimer's disease Vascular Dementia Alzheimer's disease Vascular Dementia 
Age 
category Incidence Incidence Incidence Incidence Incidence Incidence 
(years) rate 95%CI rate 95%CI rate 95%CI rate 95%CI rate 95%CI rate 95%CI 
55-59 0 0.0-5.1 0 0.0-5.1 0 0.0-7.1 0 0.0-7.1 0 0.0-7.1 0 0.0-7.1 
60-64 0 0.0-1.8 0 0.0-1.8 0.3 0.0-2.1 0.3 0.0-2.1 0.1 0.0-0.9 0.1 0.0-0.9 
65-69 1.4 0.7-3.0 0 0.0-0.0 1.0 0.4-2.8 0.5 0.1-2.1 1.3 0.7-2.3 0.2 0.1-0.9 
70-74 4.2 2.7-6.6 0.7 0.2-2.1 3.9 2.3-6.8 0.6 0.2-2.4 4.1 2.9-5.8 0.6 0.3-1.6 
75-79 10.6 7.8-14.5 2.7 1.5-5.1 8.6 5.8-12.7 3.1 1.5-6.5 9.7 7.6-12.4 2.9 1.8-4.6 
80-84 IS.1 13.7-24.1 2.8 1.3-5.9 13.2 8.2-21.3 5.6 2.7-11.9 16.5 13.0-21.1 3.7 2.2-6.3 
85-89 34.4 26.3-44.9 5.5 2.8-11.1 36.3 22.9-57.7 8.4 3.1-22.3 34.8 27.7-43.9 6.2 3.6-11.0 
90-94 53.0 37.7-74.5 3.6 0.9-14.6 11.8 3.0-47.3 17.5 5.7-54.3 44.2 31.7-61.6 7.0 2.9-16.7 
~95 85.7 48.6-150.8 7.6 1.1-54.1 0 0.0-255.9 0 0.0-255.9 70.0 39.8-123.3 6.2 0.9-43.7 
Total 8.8 7.7-10.1 1.3 0.9-1.9 4.8 3.9-6.0 1.7 !.l-2.4 7.2 6.4-8.1 1.5 l.l-1.9 
incidence of dementia 
Table 4 shows the age-adjusted rate ratio's of dementia, Alzheimer's 
disease and vascular dementia for women compared to men. Overall, 
there was no difference in dementia incidence between men and women 
(rate ratio 1.00, 95% CI: 0.80-1.24). Also, the overall incidence of 
Alzheimer's disease did not significantly differ (rate ratio: 1.20, 95% CI: 
0.93-1.56). However, after 90 years of age, women were at higher risk to 
develop dementia and Alzheimer's disease (rate ratio dementia: 2.61, 95% 
CI: 1.04-6.56: rate ratio Alzheimer's disease: 5.79, 95% CI: 1.40-23.90). 
The incidence of vascular dementia was significantly lower for women 
compared to men at all ages (overall rate ratio: 0.57, 95% CI: 0.34-0.97). 
Table 4. Age-adjusted rate ratio of dementia, Alzheimer's disease and vascular dementia for women compared 
to men. 
Age category (ycars) All dementia types Alzheimer's disease Vascular Dementia 
55·74 0.83 (0.50-1.38) 1.12 (0.62-2.05) 0.46 (0.11-1.91) 
75·79 0.89 (0.59-1.33) 1.03 (0.62-1.69) 0.92 (0.35-·2.41) 
80-84 1.06 (0.68-1.66) 1.33 (0.76-2.31) 0.51 (0.18-1.47) 
85-89 1.02 (0.64-1.63) 0.98 (0.57-1.67) 0.69 (0.21-2.29) 
~ 90 2.61 (1.04-<;.56) 5.79 (1.40-23.90) 0.27 (0.05-1.38) 
Total 1.00 (0.80-1.24) 1.20 (0.93 1.56) 0.57 (0.34-1).97) 
Discussion 
We asscsscd the incidence of dementia in a large population based ongoing 
cohort Shldy and examined subtypes of dementia and differenccs between mcn 
and women. Up to age 90 we found no gender difference in dementia incidence, 
whereas above that age men seemed to bc at lower risk than women. The overall 
incidence of Alzhcimer's disease was similar in mcn and women. Over the age 
of 90 years the incidencc of Alzheimer's disease was higher for women than for 
men. The risk of vascular dementia was higher for men than for women across 
all age groups. 
A strength of our study is that we followcd a large cohort of elderly over a 
period of nearly ten years. We examined all participants extensively for 
dcmentia and other outcome measurements. Through the extensive monitoring 
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system we obtained a virtually complete follow-up of the cohOlt. Age-specific 
incidence rates were up to high age quite similar for both the in-person-screened 
persons and for those whose medical filcs were studied. The virtually complete 
follow-up and a large number of pcrson years of follow-up enabled us to obtain 
precise and reliable incidence rates of dementia up to high age. 
In recent years a number of population-bascd studies on the incidence of 
dementia have becn reported?, 5, 6, 8, 10 They show discrepant fmdings on 
distribution of gender and subtype. Most studies comprised no more than 2,000 
participants that were followed for 2-4 years and as a result the estimates were 
often imprecise. Moreover, in several studies the follow-up was not complete 
due to refusal. Recently, incidence data on a large Canadian cohort have been 
published.2l, 24 The Canadian Study of Health and Aging is in size comparable 
to the Rotterdam Study. To estimate incidence rates of dementia in dcceased 
persons the Canadian study used infol1nation from informants and death 
certificates, but in addition used a 13-item predictive algorithm based on 
baseline data and informant information that had been developed based on 71 
subjects. A diagnosis of Alzheimer's discase and vascular dementia was limited 
to survivors. Not surprisingly, the resulting age-specific incidence rates of 
dementia were higher than in Rotterdam and other European incidence studies.2, 
8 Although thc incidence rates for women at old age were highcr than for men, 
the difference was less pronounced in the Canadian Study than in the Rottcrdam 
Study. 
Two pooled analyses have becn done to include more person years of follow-
up in the highest age categories, The EURODEM studyl included 28,768 person 
years of follow-up and a more extensive collaborative study in Europe included 
42,996 person years of follow-up,25 Both studies found that the incidence of 
dementia and Alzheimer's disease continued to increase with age up to age 85-
90, after which rates increased in women but not in men. 
Up to high age total dcmentia incidence was comparable between men and 
women. However, after 90 years of agc the incidence of Alzheimer's disease was 
higher for women, whereas thc incidence of vascular dementia was higher for 
men. Since it has been suggested that ccrcbrovascular pathology is less often 
symptomatic in women,26 we may hypothesise that in womcn vascular demcntia 
is misdiagnosed as Alzheimer's disease. Another possibility is that this 
difference in subtype distribution is duc to a gender differcnce in strokc 
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incidence and prognosis?7 The divergence of dementia incidence between men 
and women at high age may be paltly due to survival differences between men 
and women. Possibly, selective survival of men at lower risk for dementia may 
have occurred. 
In conclusion, this large population-based study suggests that the incidence 
of dementia is similar for men and women up to high age. However, at vety old 
age the risk of Alzheimer's disease may be higher for women than for men and 
the risk of vascular dementia may be higher for men. 
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BLOOD PRESSURE 
AND DEMENTIA 

3.1 
Blood pressure and risk of dementia. Results from the 
Rotterdam Study and the Gothenburg H-70 Study 
Abstract 
The association between blood pressure and dementia is debated. Results ./i·om 
population-based studies all blood pressure alld dementia are inconclusive, and 
most are pel/armed in subjects younger than 80 years (jf age. We examined the 
relation between blood pressure and dementia and the possible effect 
modification of this relation by age in a pooled dataset based on two prospective 
population-based studies. Subjects came from the Rotterdam study (n ~ 6,668), 
a longitudinal popUlation-based study among subjects aged 55 years and ovel~ 
and ji'om the Gothenburg H-70 Study (n ~ 317), a study all subjects age 85 
years at baseline. Screening and diagnostic procedures jor assessment of 
dementia were similar at baseline and follow-up and comparable between 
studies. We estimated relative risks of demelltia using Cox' proportional hazards 
regression analysis, adjustedfor age, gender and stU(O' location. 
Average follow-up was 2.1 years. During this period 196 subjects developed 
dementia. The risk of delllentia decreased with increasing blood pressure level 
(per 10 111m Hg ;),stolic blood pressure: RR: 0.93, 95% Cl: 0.88-0.99; per 10 
mm Hg diastolic blood pressure: RR 0.89, 95% CI: 0.79-1.00). This association 
was confined to subjects who used antihypertensive medication. Persons who 
were demellled at baseline had a stronger blood pressure declille during follow-
up than those who were non-demented. 
This study suggests an inverse association between blood pressure and dementia 
risk in elderly persons on antihypertensive medication. Possibly, they may need 
higher blood pressure levels to maintain adequate cerebral peljilsion. 
Alternatively, lower blood pressure ma), be secondaJJ' to brain lesions in 
preclinical stages (jf dementia. 
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Introduction 
There is increasing evidence that vascular risk factors are associated with 
different forms of dementia. I, 2 Hypertension is one of the most important risk 
factors for stroke and coronaty heart disease, and has been reported to be a risk 
factor for both Alzheimer's disease and vascular dementia. I This relation seemed 
supported by a recent trial where antihypertensive treatment in elderly people 
with isolated systolic hypertension was associated with a lower incidence of 
dementiaJ However, results from cross-sectional observational studies are 
inconclusive. Both high4, 5 and low2, 6-8 blood pressure have been associated 
with cognitive impairment, dementia and subtypes of dementia_ Others found no 
association.9, 10 Longitudinal studies suggested that increased systolic blood 
pressure predicts reduced cognitive function or dementia 15-25 years later. I 1-13 
However, when the blood pressure was measured at the time of cognitive testing 
at high age, lower blood pressure was associated with lower cognitive 
performance or dementia'?, 8, 12 It is not clear whether low blood pressure is a 
cause or a consequence of dementing disorders'?, 8 Furthermore, relatively few 
data are available on the relationship between blood pressure and incident 
dementia, especially in the velY old. Most population-based studies do not have 
enough subjects in the highest age categories to show any significant results. To 
overcome these power problems, we combined the data of two comparable 
population based studies in order to investigate the relation between blood 
pressure and risk of dementia in different age categories. 
Matel'ials and methods 
Study population 
Data were pooled from two population-based studies: the Rotterdam Study and 
the J-J-70 Study from Gothenburg, The Medical Ethics Committee approved both 
studies and informed consent was obta ined of all participants. The Rotterdam 
Shldy is a population-based prospective cohort Shldy among persons aged 55 
years and older, including those living in institutions. 14 Baseline examinations 
took place between 1990 and 1993. During this period, 7,528 (94.3 % of total 
cohOlt) underwent extensive screening for dementia. IS Dementia diagnosis was 
made in 482 persons, of whom 339 had blood pressurc measurements at 
baseline. Of those without dementia, 378 (5.4 %) subjects were excluded 
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because of missing data on blood pressure measurements. The remaining 6,668 
were followed for an average of 2.1 years, until the second round of 
examinations in 1993 and 1994. At these examinations, 5,468 (82.0 %) 
participants were screened for dementia. Information was obtained from close 
infol1nants and general practitioners on those subjects who died before follow-
up (5.4%) or were not re-examined in person (12.6%).16 
The H-70 study is a longihldinal population Shldy of 70-year-olds in 
Gothenburg, which started in 1971. In 1986-87, all 85-year olds born between 
July 1st, 190 I and June 30th, 1902, registered for census purposes in 
Gothenburg, Sweden, were invited to take pmt in a health survcy. Both people 
living in the community and those in institutions were included. A 
neuropsychiatric examination was performed on a systematic subsample (n = 
494), which has been described in detail elsewhere. 17 Diagnosis of dementia was 
made in 147 subjects, of whom 140 had blood pressure recordings at baseline. 
The remaining 347 subjects were followed till the second examination three 
years later when the subjects were 88 years old (mean follow-up 2.2 years). Of 
those, 188 (54.2%) subjects were re-examined by a psychiatrist, 73 (21.0%) had 
died and 86 (24.8%) refused examinations. Information on 132 of those who 
deceased or refused was obtained from medical records or other sources. 
Sufficient information was thus obtained on 320 subjects18 Three individuals 
had no blood pressure recordings at age 85, leaving 317 non-demented subjects 
at risk for dementia to be included in this study. 
In both shldies subjects who had repeated blood pressure examinations were 
younger than subjects who had their blood pressure only measured at baseline. 
However, baseline blood pressure levels and gender distribution were similar. 
Diagnosis of dementia 
In the Rotterdam Shldy dementia screening and diagnosis during baseline and 
follow-up followed a three-step protocol, as described in detail elsewhere,15 
Dementia diagnosis was made according to internationally accepted criteria l9-21 
by a panel that reviewed all existing information. 
The neuropsychiatric examinations in the H-70 Shldy were performed by 
trained psychiatrists, in the subject's home or at instihltions. 17 Identical 
procedures for the diagnosis of dementia were used at ages 85 and 88. 18 These 
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were based on the neuropsychiatric examination and the close informant 
interview, using internationally accepted criteria. 19, 21,22 
Blood pressllre alld other baseline measllrements 
In the Rotterdam Shldy blood pressure was measured in sitting position at the 
right upper arm with a random-zero sphygmomanometer. The average of two 
measurements, separated by a count of the pulse rate, was used in the analysis. 
During an interview at home a trained research assistant registered current drug 
consumption. Of instihltionalised participants, medication was reported by the 
medical staff. In the H -70 study blood pressure was measured in sitting position 
at the right upper ann after 5 minutes rest using a mercUlY manometer. Systolic 
and diastolic blood pressure were registered to the nearest 5 mm Hg. During a 
house call, a registered nurse registered prescribed and aChmlly taken 
medication.2l The following variables were measured and tested as possible 
confounders or intermediates: baseline Mini-Mental State Examination 
(MMSE), diabetes,24 education dichotomised in less than 7 years of education or 
more, and smoking at baseline categorised as never, past and current smoking. In 
both shldies a histOlY of stroke was assessed at baseline and verified with 
medical records by a neurologist and a history of myocardial infarction was 
assessed by direct questioning and on ECG. 
Data analysis 
Differences in baseline characteristics between the two study populations above 
age 85 years were tested with analysis of covariance, adjusting for age and 
gender. The relative risk of dementia by increase in systolic or diastolic blood 
pressure was calculated with Cox' proportional hazards regression and presented 
with a 95% confidence interval (95% CI), controlling for age, gender and Shldy 
population. This was done using blood pressure both as a continuous (per 10 n11n 
Hg) and as a categorical variable in the propmiional hazards regression model. 
We examined if gender or age modified the relation by calculating relative risks 
for men and women separately, and in strata of age (below 75, 75 to 85, and of 
85 years and older). To check if associations could be attributed to confounding, 
analyses were repeated with possible confounders (use of antihypertensive 
medication, diabetes, smoking, education, history of myocardial infarction and 
histmy of stroke, baseline MMSE) added to the models. We examined the role 
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of antihypertensive medication use on blood pressure and dementia by 
performing a stratified analysis. 
Heterogeneity between the Rotterdam Study and the Gothenburg H-70 study 
with regard to the relation between blood pressure and dementia was tested 
using an interaction term for blood pressure and place of residence. Because this 
interaction term was non-significant (p = 0.54), we were able to pool the data on 
subjects aged 85 and over from the two studies, adding an indicator for place of 
residence. All analyses were also performed for major subtypes of dementia. 
Finally, we examined blood pressure change during follow-up. We therefore 
compared this change between dementia patients (both prevalent and incident) 
and non-demented participants at both occasions with linear regression analyses 
adjusting for age and gender. 
Table 1. Baseline characteristics of the study population, means (SD) or percentages (%). 
55-74 years 75-84 years 285 years Total population 
(N= 4987) (N ~ 1336) (N ~ 662) (N ~ 6985) 
Baseline age (yrs) 64.9 (5.5) 79.2 (2.8) 87.1 (2.8) 69.7 (9.3) 
Gender (%women) 56.9 64.6 74.0 60.0 
Antihypertensive drugs (%) 27.5 44.4 49.9 32.9 
Baseline SBP (mm Hg) 136.8 (21.4) 146.3 (22.8) 155.1 (24.9) 140.3 (22.8) 
Baseline DBP (mm Hg) 74.2 (11.2) 72.3 (12.2) 75.3 (13.1) 74.0 (11.6) 
SBP = systolic blood pressure, DBP = diastolic blood pressure 
Results 
Baseline characteristics are given in Table I. During a follow-up period of 2.1 
years 134 subjects of the Rotterdam Study (RS) and 62 subjects of the 
Gothenburg H-70 study (GS) developed dementia. Baseline and follow-up blood 
pressure above age 85 were higher in Gothenburg compared to Rotterdam (p < 
O.OOI)(data not shown). Use of antihypertensive medication was similar (RS: 
52.6%, GS: 41.1 %, p = 0.25). At old age, the incidence of Alzheimer's disease 
was similar in both studies (RS: 35.411,000 pyrs, GS: 40.211,000 pyrs). 
However, the incidence of vascular dementia was higher in Gothenburg 
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(36.1/1,000 pyrs) than in Rotterdam (9.8/1,000 pyrs). Follow-up blood pressure 
measurements were available for 5,583 (83.7%) subjects without dementia at 
baseline and for 153 (32.0%) subjects with dementia at baseline. 
Adjusted relative risks of dementia per 10 mm Hg increase in baseline blood 
pressure are given in Table 2. Overall, lower systolic and diastolic blood 
pressure at baseline were associated with a higher risk of dementia at follow-up. 
The relative risk tended to decrease with increasing age. Stratified analyses on 
antihypeltensive drug use revealed that tllis association was only (ound among 
antilwpeltensive drug users. The risk of dementia was not associated with blood 
pressure levels in subjects who did not use antihypertensive medications at 
baseline (Figure I). 
Systolic blood preSsure Diastolic blood pressure 
4 4 
3 3 
o o 
< 120 120-160 >= 160 <70 70-80 >= 80 
ffiIIlllg mmHg 
II no antihypertensive Rx 0 antihypertensive Rx II no antihypertensive Rx 0 antihypertensive Rx 
Figure 1. Antihypertensive medication use (Rx) and relative risk of dementia. 
Left: three categories of blood pressure level, stratified on medication use: < 120, 120·160, ~160 mm Hg, 
lowest category without medication as reference. 
Right: three categories of blood pressure level, stratified on medication use: < 70, 70-80, ~ 80 nlln Hg, lowest 
category without medication as refercnce. 
The association between lower systolic and diastolic blood pressure at baseline 
and the risk of demcntia at follow-up was observed across all age strata, in men 
as well as in women and both in Alzheimer's disease and vascular dementia 
(Table 3). When we adjusted for possible confounders (education, smoking, 
antihypertensive medication, diabetes, histOlY of stroke and history of 
myocardial infarction, baseline MMSE) the estimates did not change (data not 
shown). 
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rable 2. Adjusted relative risk for dementia associated with baseline blood pressure*. 
55-74 years 75-84 years <: 85 years Total 
N (number of demented) N =4987 (25) N = 1336 (68) N = 662 (103) N = 6985 (196) 
RR (95% el) RR (95% el) RR (95% el) RR (95% el) 
SBP (per 10 mm Hg) 
Total population 0.96 (0.80-1.16) 0.95 (0.85-1.06) 0.89 (0.82-0.97) 0.93 (0.88-0.99) 
No antihypertensive Rx 1.06 (0.83-1.35) 1.00 (0.86-1.17) 0.96 (0.85-1.07) 1.00 (0.92-1.09) 
Antihypertensive Rx 0.84 (0.62-1.13) 0.92 (0.78-1.07) 0.83 (0.72-0.94) 0.86 (0.78-0.95) 
DBP (per 10 mm Hg) 
Total population 0.93 (0.65-1.32) 0.95 (0.77-1.16) 0.82 (0.70-0.97) 0.89 (0.79-1.00) 
No antihypertensive Rx 0.93 (0.59-1.48) 1.09 (0.84-1.42) 0.82 (0.66-1.03) 0.95 (0.82-1.12) 
Antihypertensive Rx 0.91 (0.51-1.62) 0.83 (0.61-1.13) 0.80 (0.62-1.03) 0.82 (0.68-0.98) 
* Adjusted for age, gender and study population 
SBP = systolic blood pressure, DBP = diastolic blood pressure, Rx = medication 
Table 3. Adjusted relative risk for subtypes of dementia associated with baseline blood pressure'. 
Total AD AD without eVD AD with Vascular dementia 
(number of demented) (124) (106) eVD (18) (46) 
RR (95% el) RR (95% el) RR (95% el) RR (95% el) 
SBP (per 10 nun Hg) 
Total population 0.96 (0.89-1.03) 0.92 (0.85-1.00) 1.18 (0.98-1.42) 0.93 (0.82-1.06) 
No antihypertensive Rx 1.02 (0.92-1.14) 0.97 (0.87-1.08) 1.36 (1.05-1.76) 1.04 (0.89-1.21) 
Antihypertensive Rx 0.91 (0.81-1.02) 0.89 (0.79-1.01) 1.02 (0.76-1.36) 0.77 (0.61-0.97) 
DBP (per 10 nun Hg) 
Total population 0.94 (0.82-1.09) 0.91 (0.77-1.06) 1.17 (0.81-1.69) 1.01 (0.79-1.28) 
No antihypertensive Rx 0.97 (0.79-1.18) 0.90 (0.72-1.13) 1.37 (0.87-2.16) 1.09 (0.82-1.45) 
Antihypertensive Rx 0.93 (0.74-1.16) 0.93 (0.73-1.18) 0.91 (0.51-1.63) 0.89 (0.59-1.34) 
'Adjusted for age, gender and study population 
AD = Alzheimer's disease, CVD = cerebrovascular disease 
SBP = systolic blood pressure, DBP = diastolic blood pressure, Rx = medication 
Blood pressure (lnd dementia 
Dementia appeared associated with a decrease in blood pressure during follow-
up (Figure 2). In all age categories we observed a larger decrease in blood 
pressure in prevalent dementia patients compared to subjects without dementia. 
Subjects with incident dementia also decreased more in blood pressure level than 
persons without dementia. This difference however was not statistically 
significant. 
2 
SBP DBP .. no dementia 
0 
o dementia during follow-up 
'" 
o dementia :at baseline 
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Figure 2. one-year change in blood pressure. Subjects ,vilhont dementia compared 10 subjects with prevalent 
or incident dementia. 
DisclIssion 
We found that both baseline systolic and diastolic blood were inversely 
associated with the risk of dementia, but only in subjects who used 
antihypertensive medication. 
Major advantages of the Rotterdam Study and the Gothenburg H-70 study to 
investigate risk factors and predictors for dementia are the longitudinal and 
population-based design, the fact that blood pressure was assessed before onset 
of dementia, and the complete (Rotterdam Study) or nearly complete 
(Gothenburg H-70 study) follow-up of the population at risk of dementia. By 
pooling the data of the two studies we were also able to reach firm results in the 
very old age group. There were however some differences between the studies. 
The Rotterdam Study used a three phase comprehensive diagnostic work-up 
including a screening phase for dementia detection. Although this procedure has 
a high sensitivity and specifieityl4, 15, 25 we may have missed some cases of 
dementia. In the H-70 study all subjects were examined by a psychiatrist and all 
subjects had a close informant interview. The incidence of dementia in the H-70 
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study was higher compared to the Rotterdam Study. This difference was mainly 
caused by a higher incidence of vascular dementia. The incidence of 
Alzheimer's disease was identical. Blood pressure was higher in Gothenburg 
than in Rotterdam both in demented and in non-demented individuals. 
Differences of this magnitude however are very common between different 
studies, even if they take place in the same country. These differences can 
possibly be explained by a difference in the way of blood pressure assessments 
between both shldies26 or by a difference in time of measurement between the 
shldies (H-70: 198611987; RS: 199011993) causing a period effect in blood 
pressure levels.27 Therefore, we assume that the differences between the two 
studies are not related to the outcome. 
Few longihldinal population based studies have examined blood pressure and 
dementia in the velY old. Recently, in line with our findings, the Kungsholmen 
Project reported that non-demented individuals with a systolic blood pressure 
below 140 nUll Hg were at increased risk of dementia during a tlu'ee year follow-
up.28 However, in that Shldy also a baseline systolic blood pressure above 180 
nUll Hg was related to an increased risk of dementia, a finding that we could not 
confirm. Several shldies have reported that high blood pressure in nudlife is 
related to low cognitive perfonllance in old age.12, 13, 29 In one of these, the 
Honolulu-Asia Aging Study, a low blood pressure was associated with lower 
cognitive performance in a cross-sectional analysis at the time of cognitive 
testing. This is in line with a previous report from the Gothenburg Study that 
blood pressure levels of those who developed dementia between age 79 and 85 
were increased at age 70 years but declined thereafter at a faster rate than in 
those who did not develop dementia. Indeed, in that Shldy, blood pressure tended 
to be lower in the years directly preceding dementia. II Tlus also concurs with 
several cross-sectional shldies that showed that above age 75 years low blood 
pressure is related to low coglutive performance2 or dementia.6, 7 Consequently, 
the follow-up period in our present Shldy may have been too short to find the 
long-term effect of elevated blood pressure. 
Our main finding that low blood pressure increases the risk of dementia after 
two years may either reflect that low blood pressure causes or contributes to 
dementia or that incipient dementia leads to a drop in blood pressure. As for the 
first explanation, we observed an inverse association between blood pressure and 
dementia mainly in subjects who used antihypertensive medication. 
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Antihypertensive medication probably reflects hypertension of longer duration, 
even if the blood pressure is normalised at the time of measurement. One could 
consider that subjects who use antihypertensive medication are the subjects with 
the more severe atherosclerosis and are more susceptible to pressure drops 
causing inadequate blood flow through the brain. Systemic hypotension with 
associated reduced cerebral blood flow may give rise to a spectrum of ischaemic 
neuronal lesions in vulnerable areas of the brain,3o especially in watershed 
areas30, 31 and may also lead to ischaemic loss of myelin in the white matter.32 
Persons who survive until old age, despite atherosclerotic lesions, may require 
increasing levels of blood pressure to maintain adequate cerebral blood flow. In 
that situation, low blood pressure can result in chronic hypoperfusion, which 
then could lead to cognitive impairment and dementia. 
A second explanation for our findings could be that low blood pressurc is a 
consequence of incipient dementia. In support of this, we found that blood 
pressure was lower in subjects with manifest dementia at baseline and declined 
more rapidly in this group than in the non-demented during follow-up. These 
findings are supported by reports that blood pressure declines in the years 
preceding dementia onsetll and further declines during the course of Alzheimer's 
disease.33 Several areas that are involved in central blood pressure regulation are 
affected in Alzheimer's disease. Burke et al reported a strong correlation 
between the number of Cl neurones in the medulla oblongata and blood pressurc 
in Alzheimer patients.3) Skoog et al repOlted that cerebral atrophy was 
correlated to lower blood pressure in 85-year-olds.7 Cross-sectional studies in 
younger age groups generally report a lower cognitive performance in 
hypertensives compared to normotensives.34, 35 It is possible that the subtle 
cognitive impairment reported in middlc-aged and younger elderly hypertensives 
are early manifestations of subclinical neurodegenerative processes that 
ultimately may lead to both dementia and low blood pressure. 
It is also possible that both mechanisms are involved, but act in different 
subgroups. This would fit observations that low blood pressure increases the 
short-term mortality but predicts better long-term survival. Apparently, elderly 
persons with low blood pressure are a mixture of two subgroups: people with 
low blood pressure due to multiple chronic diseases, including atherosclerosis, 
and people with low blood pressure who are in good health.36 
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In sunUllaty, our results show that baseline blood pressure predicts dementia in 
elderly who use antihypertensive medication. Whether low blood pressure is 
causally related to demei,tia or the result of the dementia process still remains 
unclear. Prospective shldies with a longer duration of follow-up are required to 
fmiher unravel the relation between blood pressure and dementia. 
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Abstract 
3.2 
Blood pressure and risk of dementia: 
the Rotterdam Study 
Background Hypertension increases the risk of stroke and vascular dementia, 
but has also been suggested to increase the risk of Alzheimer's disease. Studies 
with long duration lend support for this suggestion. However, studies with short 
duration have found that loll' blood pressure increased the risk of Alzheimer's 
disease. We examined the association between level of blood pressure and 
change in blood pressure and the risk of dementia. 
Methods The study is based on 6,141 participants of the Rotterdam Study, a 
population-based study on subjects aged 55 years and over in Rotterdam, the 
Netherlands, who had their bloodpressure assessed at baseline (1990-1993) and 
were still alive and non-demented at the first follow-up examination (1993-
1994). The cohort wasfollowedfor incident dementia until December 31,1999. 
Findings During 24,692 person-years of follow-up 211 persons developed 
dementia. Higher baseline blood pressure levels were associated with an 
increased risk of dementia (relative risk (RR) perl 0 mm Hg increase in SBP: 
1.05, 95% C1 0.99-1.12; DBP: RR 1.07, 95% Cl: 0.95-1.21), especially for 
persons aged 55-75 years (SBP: RR 1.18, 95% CJ: 1.06-1.31; DBP: RR 1.24, 
95% C1: 1.01-1.51). Persons with a more than 5 mm Hg decline in blood 
pressure between baseline andfirst follow-up were at increased risk of dementia 
compared to persons with stable blood pressure levels (SBP: RR 1.95, 95%C1: 
1.31-2.89; DBP: RR 1.81, 95%CJ: 1.22-2.68). Relations were strongest for 
vascular dementia, but also present for Alzheimer's disease. 
Interpretation These .findings are compatible with the view that high blood 
pressure increases the risk of Alzheimer's disease. A decline in blood pressure 
may either be a cause 01' a consequence of the dementia process. 
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Introduction 
Hypertension is an established risk factor for stroke and vascular dementia. l 
Recently hypertension has also been suggested as a possible risk factor for 
Alzheimer's disease2 , 3 A link between hypeliension and Alzheimer's disease 
seems suppOlied by a recent trial in which antihypertensive treatment in elderly 
people with isolated systolic hypertension was associated with a lower incidence 
of Alzheimer's disease.4 Follow-up shldies with long duration generally showed 
high blood pressure to be associated with an increased risk of Alzheimer's 
disease.2,3 By contrast, studies with short duration suggested that hypertension is 
associated with a lower risk of Alzheimer's disease.5-7 
We examined the relation between the level of blood pressure and the change 
in blood pressure and the risk of dementia, using data from the Rotterdam Study, 
a large follow-up study conducted in the Netherlands. 
Methods 
Study population 
The Rotterdam Shldy is a population based prospective cohort Shldy among 
7,983 persons aged 55 years and older, including those living in institutions.8 
The Shldy was approved by the Medical Ethics Committee of the Erasmus 
University. Pmiicipants gave written infonned consent and permission to 
retrieve information from treating physicians. At baseline (1990-1993), 7,528 
subjects (94.3% of the total COhOli) underwent extensive screening for dementia9 
and 482 persons were identified with prevalent dementia, The cohort was re-
examined in 1993-1994 and in 1997-1999, In addition, the total cohort is 
continuously monitored for incident dementia cases via computerised linkage 
between the study database and medical records from general practitioners and 
the Regional Instihlte for Outpatient Mental Health Care (RIAGG),9 
Of the 7,046 subjects at risk for dementia 6,668 had blood pressure 
measurements available at baseline. We excluded 20 persons of whom we were 
unable to obtain sufficient information on dementia status at the end of their 
second follow-up period, Since we hypothesised that the short-term relation 
between blood pressure and risk of dementia lllay be different from the relation 
over a longer period, and we therefore also wanted to investigate change in 
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blood pressure in relation to risk of dementia, we excluded the fIrst follow-up 
period (14,090 person-years (on average 2.1 years» from the analyses. In tltis 
period 137 subjects developed dementia and an additional 370 died. Our 
analytical samplc therefore effectively consisted of the 6,141 persons who were 
alive and non-demented at the fIrst follow-up examination. 
Diagnosis of dementia 
Dementia screening and diagnosis during baseline and follow-up examinations 
were similar.9 Briefly, all subjects were screened with a shOlt test of cognition 
(Mini Mental State Examination lO and the Geriatric Mental State schedule, 
orgattic level I I ). Screen positives underwent fmther cognitive testing, and an 
informant interview was obtained. Persons suspected of dementia werc 
examined by a neurologist and underwent neuropsychological testing. To 
differentiate vascular dementia from Alzheimer's disease a brain scan was made 
by magnetic resonance imaging (MRI) or computed tomography (CT). Dementia 
diagnosis was made according to internationally accepted criteria (NINCDS-
ADRDA, NINDS-AIREN, DSM-IIl-R) by a panel that reviewed all existing 
information.9,12-14 
Blood pressure and other baseline measurements 
Baseline and follow-up blood pressure levels were measured in sitting position 
at the right upper arm with a random-zero sphygmomanometer. The average of 
two measurements, separated by a count of the pulse rate, was used in the 
analysis. Pulse pressure was defIned as the difference between systolic and 
diastolic blood pressure. At baseline and first follow-up participants were asked 
to report and show all medication used during the week preceding the interview. 
Subsequently, all dmgs were classifIed according to their corresponding 
Anatomical-Therapeutical-Chemical-code (A TC-code). 
The following baseline variables were used as possible confounders: 
diabetes, defIned according to WHO criteria for epidemiological studies of 
diabetes as the use of antidiabetes medication or a random or post-load serum 
glucose level greater than II n1111olll; 15 education, dichotomised in primary 
education or less and more than primaty education; smoking, categorised as 
nevel', past and current smoking; total cholesterol (mmolll); body mass index 
(weight (kg)/height (m'»; and blood pressure lowering medication. A history of 
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stroke was assessed at baseline and verified with medical records by a 
neurologist and a histOlY of myocardial infarction was assessed by direct 
questioning and verified by ECG and general practitioner or cardiologist. 
Apolipoprotein E (APOE) genotyping was performed on coded DNA samples 
without knowledge of the diagnosis. The polymerase chain reaction product was 
digested with the restriction enzyme mw!' and fragments were separated by 
electrophoresis.!6 
Statistical analysis 
The relative risks of dementia by levels of baseline systolic and diastolic blood 
pressure and by levels of pulse pressure were calculated with Cox' proportional 
hazards regression and presented with a 95% confidence interval (95% CI), 
controlling for age, age', and gender. This was done both by entering blood 
pressure as a categorical (quintiles) and as a continuous variable in the 
proportional hazards regression model. We examined if gender or age modified 
the relation in subanalyses where we stratified by gender and age (55-74, 75 
years and older). In addition, age and gender were evaluated for potential 
interaction with blood pressure by adding separate terms to the regression 
models (age (continuously) x blood pressure (continuously); gender x blood 
pressure (continuously». To check if associations could be attributed to 
confounding, analyses were repeated with possible confounders added to the 
models. We repeated the analyses excluding persons on blood pressure lowering 
medication at baseline. 
For the analysis on change in blood pressure level between baseline and first 
follow-up, we excluded 842 persons (13.7 %) who had no second blood pressure 
measurement. The risk of dementia was calculated using change in blood 
pressure per year as a categorical variable (increase> 5 nun Hg; increase <; 5 to 
a decrease < 5 nun Hg; decrease ~ 5 nun Hg) in the proportional hazards 
regression model. All analyses were adjusted for age, age' and gender. Because 
baseline blood pressure level may be correlated to change in blood pressure we 
repeated the analyses adjusting for baseline blood pressure level. However, since 
adjusting for baseline level may cause bias due to regression towards the mean!7 
and because the results did not differ from the unadjusted relative risks, we 
present the analyses unadjusted for baseline blood pressure levels. All analyses 
were repeated adjusting for possible confounders. In addition, we repeated the 
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analyses excluding persons on blood pressure lowering medication either at 
baseline or at first follow-up examination. 
To account for misclassification of subtypes of dementia, we performed 
additional analyses restricted to those cases where the dementia diagnosis was 
supported by neuroimaging (either MRI or CT). 
Table 1. Baseline characteristics of participants ofthe Rotterdam Study, 
Total Population 55-74 years ;;:: 7S years 
(n ~ 6,141) (n~4,817) (n~ 1,324) 
Age (years) 6S.2 (S.3) 64.8 (5.4) 80.4 (4.3) 
Gender (% women) 59.6 57.3 6S.0 
Dlood pressure lowcring dmgs (%) 30.3 26.7 43.4 
Systolic blood pressure (mm Hg) 139.1 (22.1) 136.7 (21.4) 147.8 (22.6) 
Diastolic blood pressure (mill JIg) 73.9 (l1.3) 74.3(11.1) 72.7 (12.0) 
Pulse pressure (mm Hg) 65.1 (17.7) 62.4 (16.6) 75.1 (18.3) 
Diabetes (%) 9.4 8.0 14.5 
Smoking: Current (%) 22.8 25.2 14.0 
Fonllcr(%) 42.5 44.4 35.6 
Never (%) 34.6 30.4 50.4 
Primary education or less (%) 35.9 30.9 54.4 
Total cholesterol (mmolll) 6.7 (1.2) 6.7 (1.2) 6.5 (1.3) 
Body mass index (kg/m2) 26.4 (4.0) 26.3 (4.0) 26.6 (4.0) 
Figures are proportions (%) or means (SD) 
Results 
Baseline characteristics are given in Table I. During a total of 24,692 person-
years of follow-up 211 participants developed dementia. Alzheimer's disease 
was diagnosed in 158 patients (74.9%) (148 without and 10 with cerebrovascular 
disease), vascular dementia was diagnosed in 32 patients (15.2%) and 21 
subjects (10.0%) were diagnosed with other dementia. We obtained 
neuroimaging in 93 dementia cases (44.0%; 39.9% of Alzheimer cases and 
68.8% of vascular dementia cases). 
Non-responders to the first follow-up examination were on average older, 
were more frequently female and had higher baseline systolic and diastolic blood 
pressure levels compared to responders. Mean change in systolic blood pressure 
was l.l mm Hg increase per year (SD 10.8), mean change in diastolic blood 
pressure was 1.4 nnn Hg increase per year (SO 6.5). 
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Adjusted relative risks of dementia and subtypes of dementia per 10 lrull Hg 
increase in baseline blood pressure level are given in Table 2. Increasing 
baseline systolic and diastolic blood pressure levels and increasing pulse 
pressure levels were associated with an increased risk of dementia, particularly 
in younger subjects (interaction between age and systolic blood pressure: p = 
0.013). The association was present for both Alzheimer's disease and vascular 
dementia. 
Table 2. Adjusted relative risk for subtypes of dementia associated \vith baseline blood pressure level". 
Total population 55-74 years > 75 years 
Systolic BP (per 10 mill Hg) 
All dementia 1.05 (0.99·1.12) !.I8 (1.06·1.31) 0.98 (0.91·1.07) 
Alzheimer's disease 1.03 (0.96· !.I 1) !.I5 (1.01·1.30) 0.97 (0.88·1.07) 
Vascular dementia 1.22 (1.04·1.43) 1.37 (1.04·1.81) 1.10 (0.S9·1.35) 
Diastolic BP (per 10 mill Hg) 
All dementia 1.07 (0.95·1.21) 1.24 (1.01·1.51) 1.00 (0.S6·!.I7) 
Alzheimer's disease 1.01 (0.88·!.I7) !.I2 (0.89·1.42) 0.97 (0.82· !.I 6) 
Vascular dementia 1.42 (1.05·1.91) 2.51 (1.50-4.22) 1.03·(0.68·1.56) 
Pulse pressure (per 10 mm Hg) 
All dementia 1.05 (0.97·1.14) US (1.04·1.34) 0.97 (0.88·1.0S) 
Alzheimer's disease 1.04 (0.95·!.I4) I.IS (1.02·1.37) 0.97 (0.86·1.09) 
Vascular dementia 1.18 (O.97-1.43) l.09 (0.77-1.53) 1.14-(0.88-1.46) 
* Adjusted for age, agel, gender, diabetes, cholesterol, body-mass-index, education, blood pressure lowering 
medication, history of stroke, history of myocardial infarction, APOE genotype 
Gender specific analyses revealed no differences regarding the risk of 
Alzheimer's disease. The risk of vascular dementia was higher for men (RR per 
10 mm Hg increase in SBP: 1.38,95% CI: 1.10-1.74; DBP: RR 1.75, 95% CI: 
1.12-2.73) than for women (RR per 10 nun Hg increase in SBP 1.08, 95% CI: 
0.86-1.37; DBP: RR 1.21,95% CI: 0.80-1.84). After exclusion of persons who 
used blood pressure lowering medication at baseline the relative risks did not 
change appreciably. Also, the analyses confined to cases with neuroimaging (n = 
93) yielded similar relative risks for subtypes of dementia. 
Table 3 shows the relative risk of dementia associated with change in blood 
pressure level from baseline to first follow-up in categories of change in blood 
pressure level. A decline of more than 5 mm Hg in systolic or diastolic blood 
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pressure level was associated with an increased risk of dementia at follow-up. 
This relation was present for both Alzheimer's disease (SBP: RR 1.58, 95% CI: 
1.00-2.49; DBP: 1.81, 95% CI: 1.22-2.68) and vascular dementia (SBP: RR 
7.88,95% CI: 2.07-30.00; DBP: 2.65, 95% CI: 0.99-7.13). 
Table 3. Adjusted relative risk for subtypes of dementia associated with a change in blood pressure from 
baseline to first follow-up ( n = number of cases)"'. 
Systolic Blood Pressure 
Increase> 5 lllill Hg 
Increase ~ 5 and decrease < 5 nml Hg 
Decrease ~ 5 mill Hg 
Diastolic Blood Pressure 
All dementia 
(n ~ 159) 
1.25 (0.85-1.84) 
1.0 
1.95 (1.31-2.89) 
Alzheimer's disease Vascular dementia 
(n ~ 123) (n ~ 20) 
l.l7 (0.77-1.79) 
1.0 
1.58 (1.00-2.49) 
2.43 (0.57-10.27) 
1.0 
7.88 (2.07-30.00) 
Increase> 5 nnll Hg 0.88 (0.59-1.31) 1.00 (0.65-1.53) 0.42 (0.09-1.94) 
Increase ~ 5 and decrease < 5 nun Hg 1.0 1.0 1.0 
Decrease> 5 nnn Hg 1.81 (1.22-2.68) 1.60 (0.99-2.57) 2.65 (0.99-7.13) 
*Adjllsted for age, agel, gender, diabetes, cholesterol, bod)Hnass-index, education, blood pressure lowering 
medication, history of stroke, history oflllyocardial infarction, APOE genotype 
The association was not significantly different for men and women and similar 
for younger and older persons. Change in pulse pressure was not associated with 
risk of dementia. The analysis in which we excluded persons who used blood 
pressure lowering medication at baseline or follow-up yielded practically similar 
results for decline in systolic blood pressure (RR 2.24,95% CI: 1.26-3.99), but a 
lower risk of dementia associated with a decline in diastolic blood pressure (RR 
1.39, 95% CI: 0.73-2.62). 
Discussion 
We found that elevated blood pressure levels were associated with a long-term 
increased risk of dementia. A decline in blood pressure over a relatively short 
period was associated with an increased risk of dementia. These findings werc 
more marked for vascular dementia, but also present for Alzheimer's disease. 
A strength of our study is that we followed a large cohort of elderly subjects 
with repeated detailed examinations including dementia screening over a period 
of nearly 10 years and that follow-up was virtually complete. This allowed us to 
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investigate change in blood pressure level in relation to risk of dementia. 
However, there are some methodological issues that need to be discussed. First, 
subjects had to survive long enough to obtain a second blood pressure 
measurement. Subjects who died between baseline examination and first follow-
up may have had a more severe decline in blood pressure compared to those who 
survived. IS This could however only have led to an overestimation of the relative 
risk if the mortality rate was higher in non-demented than in demented, and we 
consider that unlikely. Second, one might consider that we have overestimated 
the relative risk of Alzheimer's disease due to misclassifieation of cases with 
vascular dementia into Alzheimer's disease. Although exclusion of dementia 
patients without neuroi.l11aging did not change our results, we can not entirely 
exclude this possibility. 
Our findings lend further SUppOlt to the notion that high blood pressure may 
increase the long-term risk of low cognitive perfolluanee l9.22 and dementia.2. 3 
The studies on dementia reported up to now comprised only men3 or had a 
relatively small sample size,2 but were consistent with our results. Several 
possible explanations for the long-term increased risk of dementia in participants 
with high baseline blood pressure levels may be offered. First, hypertension is a 
major risk factor for stroke and single strategic or multiple infarcts may lead to 
vascular dementia.23 Second, hypertension is the outstanding risk factor for 
cerebral white matter lesions.24, 25 These lesions are associated with cognitive 
dysfunction in non-demented subjects,26 and abundantly present in demented 
subjects.27, 28 Third, hypertension can lead to endothelial damage and impaired 
blood brain barrier function. 29 Alterations in the blood brain barrier function may 
impai.r the transport of crucial nutrients and metabolites to the brain or allow 
circulating toxic agents to gain access to the brain tissue. It remains still to be 
elucidated whether and how this may eventually contribute to the development 
of Alzheimer's disease.28, 29 
A decline in blood pressure was associated with a short-term increased risk of 
dementia, irrespective of baseline blood pressure level. Possible explanations for 
this include that a decline in blood pressure may either be a consequence of 
dementia or be a cause of dementia. As for the first explanation, some authors 
suggested that a decline in blood pressure might be a consequence of brain 
lesions associated with dementia, since several areas that are involved in central 
blood prcssure regulation are affected i.n Alzheimer's disease.30·32 A second, but 
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equally possible, explanation is that lowering of the blood pressure beyond a 
critical threshold increases the risk of dementia through chronic hypoperfilsion, 
especially in elderly persons with longstanding hypertension.3). )4 Based on 
current existing data it is impossible to judge whether the flrst explanation, the 
second explanation, or a combination of both accounts for the association 
between a decline in blood pressure and developmcnt of dementia. 
Our study suggests that it may be important to closely monitor blood pressure 
levels in the elderly and SUppOlts the hypothesis that early control of high blood 
pressure may reduce the risk of dementia in the elderly. 
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Abstract 
3.3 
Blood pressure medication and risk of 
dementia: the Rotterdam Study 
There is increasing evidence that hypertension may contribute to the 
development of dementia. We investigated the relation of antihypertensive drug 
use and the risk of dementia in the cohort of the population based Rofferdam 
Study. The study cohort included 7,046 elderly, Fee of dementia at baseline. 
Dementia was diagnosed in a stepwise procedure. Participants were first 
screened Screen positives were jitrther tested Those suspected of dementia 
underwent a diagnostic work-up. Dementia and its subtypes were diagnosed 
according to prevailing criteria. A Cox' proportional hazards model was used to 
estimate relative risks. Afier a mean follow-up of 2.2 years, subjects taking 
antihypertensive medication at baseline (n=2,015) had a reduced incidence of 
dementia (adjusted relative risk, 0.76; 95% confidence interval 0.52-1.12). This 
risk reduction was most pronounced for vascular dementia, (adjusted relative 
risk, 0.30; 95% cOlifidence interval 0.11-0.99). For Alzheimer's disease the 
relative risk was 0.87, not significant. Dementia ma), be prevented by 
antihypertensive treatment. In order to cOIifirm any relation in Alzheimer's 
disease larger obsel1'ational studies with longer follow-up are needed 
Introduction 
There is increasing evidence that hypertension may contributc to the 
development of cognitive impairment and dementia, 1-4 although there is celtainly 
no general agreement on the mechanism.' This logically leads to the hypothesis 
that lowering of the blood pressure with antihypertensive treatment might 
protect against the development of cognitive dysfunction and dcmcntia. 
In the Framingham Heart Study, there was no longitudinal association after 
over IS years of follow-up bctween cognitive function and blood pressure 
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among subjects using antihypertensive dl11gs. However, in untreated subjects 
both higher systolic and diastolic blood pressure, were associated with worse 
cognitive performance later in life: In a recently published 20-year follow-up 
study, it was also shown that the association between hypertension at baseline 
and the development of cognitive dysfunction was strongest in untreated men: 
Until now, however, evidence of a beneficial effect of antihypettensive 
treatment on the development of dementia in epidemiological shldies is scarce. 
In the prospective population-based Kungshohnen study in subjects aged 75 
years and older, use of antihypertensive medication was studied in relation to the 
onset of Alzheimer's disease (AD). Among the non-demented subjects, persons 
with antihypettensive medication in general and diuretic monotherapy at 
baseline had a significantly reduced risk of developing both total dementia and 
AD." 8 Other evidence comes from the Systolic Hypertension in Europe trial 
(Syst-Em), in which treatment of isolated systolic hypertension with nitrendipine 
was associated with a borderline significant protective effect for total dementia. 
However, follow-up time was short (median 2 years) and numbers of demented 
subjects were very small in this study: 
It is now clear that treatment of hypertension leads to a risk reduction of both 
cardiovascular morbidity and mOttality. A possible consequence is that ethical 
problems will arise in the design and conduct of futurc clinical trials to assess 
the effect of blood pressure lowering on the risk of dementia. Therefore we 
investigated the association between use of antihypertensives and the incidence 
of dementia in the Rotterdam Study, a large observational prospective 
population based study. 
Methods 
Study populatioll 
The Rotterdam Study tS a prospective population-based cohOtt study of 
neurological, cardiovascular, locomotor and ophthalmological diseases in the 
elderly. Aftcr approval of thc Medical Ethics Committee, all inhabitants of 
Ommoord, a suburb of Rotterdam in Thc Netherlands, aged 55 years or more 
and living in the district for at least one year wcre invited in 1990-1993 to 
participate in the Shldy. Of the 10,275 eligible subjects, 7,983 (78%) participated 
and signed informed consent. During thc home intervicw, trained intcrviewers 
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administered a questionnaire covering, among other topics, socia-economic 
background, medical histOlY and medication use. During subsequent visits to the 
research center, subjects underwent additional interviewing and clinical 
examinations, including screening and diagnosis of dementia. Complete data on 
dementia were available in 7,528 subjects. A diagnosis of dementia was made in 
482 persons. The remaining 7,046 non-demented subjects were followed for an 
average of 2.2 years until the second round of examinations in 1993 and 1994. 
At these examinations, 5,571 (79%) participants were actively screened for 
dementia. Of 999 (14%) subjects who were not re-examined and 476 (7%) who 
died during follow-up, information on cognitive function was obtained from 
close informants and general practitioners. 
D}'[(g e.\poslII·e and other base/ine measllrements 
During the home interview participants were asked to report and show all 
medication used during the week preceding the interview. Subsequently, all 
drugs were classified according to their corresponding Anatomical-
Therapeutical-Chemical-code (ATC-code).l0 For the current study, a 
classification was made according to the nahu'e of the dmg-class: diuretics, beta-
blockers, ACE-inhibitors, calcium channel blockers and other antihypertensives. 
We assumed that dmgs with antihypertensive properties were used clu'onically, 
as hypertension rarely subsides spontaneously. At the research center height and 
weight were measured. Blood pressure was measured in the sitting position at 
the right upper ann with a random-zero sphygmomanometer and calculated as 
the mean of two consecutive measurements. Diabetes mellitus was defined as 
the use of anti-diabetic medication or at least one blood-glucose assessment 
higher than II mmolll, according to WHO-criteria for epidemiological shldies. 11 
A histOlY of stroke was assessed during the baseline interview and verified with 
medical records by a neurologist. The ratio of the systolic blood pressure at the 
ankle to the systolic blood pressure at the arm was calculated for each leg. 
Peripheral arterial disease was considered present when this anklc-ann index 
was lower than 0.9 on at least one side. 12 
In addition, prescription-filling data, provided by the 7 pharmacies in the 
Ommoord region, were available for approximately 99% of the cohort as of 
Januaty 1991. These data comprise quantitative information on each individual 
prescription. 
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Case ascertainment of dell/entia 
Both at baseline and at the follow-up examination, subjects were screened for 
dementia in a stepwise procedure. Subjects were screencd on cognitive function 
using the Mini-Mental State Examination (MMSE)13 and the Geriatric Mental 
State schedule (GMS).14 Those scoring 25 or below on the MMSE or scoring I 
or more on the GMS were selected for fmiher diagnostic evaluation. This 
included more detailed neuropsychological testing and an informant interview 
based on the Cambridge Examination for Mental Disorders of the Elderly,15 as 
well as neurological examination. Some participants underwent magnetic 
resonance imaging of the brain. A clinical diagnosis of dementia was made 
according to the DSM-ill-R criteria for dementia by a panel that reviewed all 
existing information. A sub-diagnosis of AD was made according to the 
NINCDS-ADRDA critcria. 16 A sub-diagnosis of vascular dementia was made in 
accordance with the NINDS-AIREN criteria.17 After a mean follow-up of 2.2 
years, a total of 162 demented subjects, including 116(73%) subjects with AD, 
of which 15 also had cerebrovascular disease, and 22(14%) subjects with 
vascular dementia, were diagnosed. 
Confounding variables 
The following variables were considered possible confounders and were 
therefore entered into the statistical models: age, gender, diastolic and systolic 
blood pressure (mm Hg), history of stroke and diabetes mellitus. Additional 
adjustments were made for body mass indcx (BM!: kg/m'), smoking (never, 
fOllner, current), education «7 years, '27 years), living situation (independcnt, 
home for the elderly), baseline MMSE and peripheral arterial disease. 
Statistical analyses 
Analysis of covariance adjusted for gender and age, was used to compare 
characteristics of subjects with and without antihypertensives at baseline. We 
used Cox' proportional hazards regression analysis to calculate relative risks 
with 95% confidence intervals (95% CI) for total dementia, Alzheimer's disease 
with and without cerebrovascular disease and vascular dementia by reported use 
of antihypeliensive drugs. For categorical data with missing values we 
incorporated missing indicator variables in the model. 
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Subsequently, as we did a complete subjects analysis with rcspect to the 
continuous variables we excluded 622 subjects of whom 376 had a missing 
blood prcssure measurements, 243 a missing Mini Mental State Examination 
(MMSE) and 404 a missing body mass index (BMI). The mean age in this 
excluded group was higher than in the remainder of the population (77.6 vs. 68.6 
years), they wcre more often females (71.9% vs. 58.7%) and were far more often 
inhabitants of homes for the elderly (36.7% vs. 4.7%). 
To reduce the possibility of differential reporting of dmg use because of pre-
clinical dementia at baseline, in a sub-analysis, we excluded subjects who were 
diagnosed with dementia within one year after baseline examination. 
The risk of dementia in subjects with hypertension and associated co-
morbidity may be different from subjects without hypertension. In a second sub-
analysis, we therefore excluded all untrcated subjects without hypertension 
according to the WHO criteria 18 and calculated relative risks of treatment for 
dementia (sub )types. According to the WHO hypertension is defined as a 
diastolic blood pressure of at least 95 nun Hg andlor a systolic blood pressure of 
at least 160 nun Hg. 
Next, we studied the effect of gender. We examined whether gender modified 
the relation by calculating relativc risks for men and women separately. To 
examine confounding by indication we stratified according to mono therapy with 
first- (diuretics/beta-blockers) and second-line antihypertensive treatment 
(remaining dmgs and combinations of dmgs). 
In order to examine whether misclassification of exposure was important in 
our study, we examined a sUb-population of our cohort that had a first time 
examination after June 30 1991 (n=5,1 0 I) and were not living in a home for the 
elderly. We used tllis cut-off, as pharmacy data were only available as of January 
1991. We then calculated the percentage of subjects that repOlted both 
antihypertensive dmg use at baseline and filled an antihypeltensive prescription 
in the 6 months before baseline examination. As the duration of a prescription is 
normally limited to 3 months it is likely that most dmgs were captured using a 
six month period. 
Finally, we examined whether a competing risk was a likely explanation for 
our findings, meaning that the encountered protective effect of antihypertensives 
may have been a consequence of increased mOltality instead of a real effect. 
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Results 
Of the 6,416 subjects included in the present study, 118 subjccts developed 
dementia, of which 82 had AD and 18 had vascular dementia. In Table I, 
baseline characteristics are given for subjects with and without exposure to an 
antihypeltensive dl11g. Mean age, diastolic- and systolic blood pressure and BMI 
were significantly higher in uscrs of antihypertcnsive dl11gs. Furthermore, 
relatively many women were users and users more frequently had diabetes, 
peripheral arterial disease and a histmy of stroke. Finally, users were less often 
current smokers than non-users. The mean MMSE, grade of education and the 
proportion of subjects living independently werc comparable between groups. 
Of the 6,416 subjects 31.3% used antihypertensive medication of which 
21.1% used mono therapy, 8.5% used two drugs and 1.7% used three or more 
drugs. In total 14.6 % reported use of beta-blockers, 15.3 % reported use of 
diuretics, 5.9 % reported use of calcium antagonists,S. 7 % reported use of ACE-
inhibitors and 1.9 % reported use of other antihypeltensives. 
Table 1. General characteristics ofparticipallts at basclillct. 
Baseline measurements Non-users Users of antihypertcnsiYC Ancova* 
N=4401 dmgs N=2015 
Age (years) 67.4 71.4 P<O.OOI 
Female gender (%) 57.0 62.5 P~0.003 
MMSE 27.6 (17-30) 27.6 (16-30) Ns 
Body mass index 25.8 27.4 P<O.OOI 
Diastolic blood pressure (l11lll Hg) 73.1 75.1 P<O.OOI 
Systolic blood pressure (mm Hg) 137.7 142.5 P<O.OOI 
Smoking (%) 
Current 24.6 18.8 P<O.OOI 
Education of more than 7 years (%) 36.1 35.6 NS 
Diabetes mellitus (%) 8.1 14.2 P<O.OOI 
Housing (%) 
Home for the elderly 4.5 5.2 NS 
Markers of vascular disease (%) 
Peripheral arterial disease 15.5 21.1 P<O.OOI 
History of stroke 1.6 3.9 P<O.OOI 
*' Age and gender adjusted analysis of covariance. 
tValues represent means or percentages 
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Table 2 shows a non-significant risk reduction for dementia in general in users 
of antihypertensive dl11gs. The risk reduction was significant and most 
prominent for vascular dementia. Furthermore, it was present independent of 
adjustments made for potential confounders. Overall there were 70 dementia 
cases in the untreated group and 48 in the treated group. 
Table 2. Use of any t)11e of antihypertensive drug at baseline and the risk of dementia expressed as 
relative risk (95% confidence interval). 
Dementia type Number of demented Relativc risk* Relative riskt 
subjects N=6416 N=6416 
Total dementia tt 118 0.76 (0.52·1.12) 0.67 (0.45·1.00) 
Total Alzheimer's disease 82 0.87 (0.56·1.37) 0.77 (0.49·1.24) 
AD without vascular pathology 68 0.94 (0.57·1.53) 0.83 (0.49·1.39) 
AD with vascular pathology 14 0.64 (0.21·1.91) 0.63 (0.20·1.93) 
Vascular Dementia 18 0.33 (0.11-0.99) 0.30 (0.09-0.92) 
*Cox' proportional hazards regression analysis adjusted for agc, gender, diastolic and systolic blood pressure, 
diabetes mellitus and stroke. 
r 
Additional adjustment for body mass indcx, baseline i'iLvISE, smoking, education, living situation and 
peripheral atherosclerotic disease. 
ttThls includes 18 subjects with an other type of dementia: Parkinson's dementia (n=4), other type (n=13) and 
undetemlined (n=3) 
Risk reduction was similar when we excluded those subjects with a diagnosis of 
dementia in the first year of follow-up or a follow·up of less than a year (number 
of demented subjects~27) (data not shown). For AD the reduction in risk was, 
although not significant, most prominent in those with vascular pathology. 
Exclusion of untreated subjects without hypertension revealed comparable risk 
estimates (Table 3). 
Table 3. Relative risk of dementia according to drug use after exclusion of all nonnotensivc subjects (diastolic 
blood pressure <95 mmHg and systolic blood pressure <160 mmHg) without treatment. 
Dementia type Number of demented subiects Relativc Risk (95% el)*' 
Total dementia 61 0.67 (0.35 to 1.32) 
Total AD 45 0.99 (0.47 to 2.12) 
Vascular Demcntia 10 0.11 (0.02 to 0.74) 
*Cox proportional hazards regression analysis adjusted for age, gender, diastolic and systolic blood pressure, 
stroke, diabetes mcllitus 
Stratified analysis revealed larger risk reductions for men (RR 0.52; 95% CI 
0.22-1.20) than for women (RR 0.93; 95% CI 0.59-1.46) and for first line 
therapy than second line therapy (data not shown) for total dementia. However, 
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in both instances confidcnce intervals overlapped largely. Stratification for 
individual drugs could not confirm earlier suggestions that calcium-channel 
blockers (RR 0.70; 95% CI 0.32-1.52) and or diuretics (RR 0.83; 95% CI 0.33-
1.30) in particular are protective in the onset of dementia. 
In those living independently at baseline the accordance of repOlted use with 
actually filled prescriptions in the pharmacy was high and not significantly 
different for both healthy subjects (IF4,703: 94.6%) and demented subjects at 
follow-up (n=40: 92.9%). 
Of the 622 subjects excluded from the analysis approximately 40% reported 
use of bloodpressure lowering drugs and the overall incidence of dementia was 
29.911 ,000 person years. 
With respect to the issue of competing risks age, gendcr, blood pressure and 
follow-up time adjusted modality was lower in the treated as compared to 
untreated subjccts with hypeltension (9.0% vs. 7.5%), although this difference 
was not significant (p=0.09). 
Discussion 
In this population based prospective cohort study, we found a risk reduction of 
dementia in users of antihypertensive drugs. This risk reduction was most 
prominent and significant for vascular dementia and more pronounced in males. 
Risk reduction for AD was, although not significant, most promincnt in those 
with concomitant vascular diseasc. 
Several issues of validity need to be discussed when interpreting these 
results, in particular potential information bias and confounding by indication. 
First, we should considcr whether misclassification of exposure may have 
affected our results. A major concern in earlier, cross-sectional or retrospective, 
drug studies on dementia was thc potential for bias due to underrepOlting of drug 
use among cases by proxy informants. Although our study only comprised 
subjects who wcre not demented at baselinc, one might fear subtle impairment of 
mcmOlY in the pre-clinical phasc of dementia and thcrefore less reliable answers 
and potentially different health related behavior. A spurious protcctive effect 
might then be the consequence of undcrreporting of antihypertensive drug use in 
cascs. To assess this problem we performed separate analyses for a sample 
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restricted to those not demented in the first year of follow-up and found similar 
risk estimates. 
Furthermore, in a Shldy on the concordance of reported cardiovascular dl1lg 
use at baselinc and the achmlly filled prescriptions in the phallllacy an overall 
high correspondence was found for participants of the Rotterdam Shldy.19 For 
the present study we examined a subset of the analytical sample and found no 
major differences between demented and non-demcnted at follow-up with 
respect to reported use and filled prescriptions in the local phallllacy. Although 
we have no information on compliance, it seems unlikely that differcntial 
misclassification of antihypertensive drug use may cxplain the results. A second 
possibility of misclassification of exposure may have occurred because patients 
were not asked how long they had been treated. As demented subjects were 
older, the probability of detection of hypeltension over time may have been 
higher and therefore also the probability of treatment may have been higher. If 
present, however, such a bias would have led us to an underestimate of the 
achml effect. 
Misclassification of hypeltension may also have happened as a consequence 
of the disease, as it has been suggested that blood pressure drops in the pre-
clinical phase of AD.'o When such a pressure drop happened before baseline this 
might theoretically have Icd to discontinuation of antihypertensive treatment and 
therefore to an underestimation of long-standing treatment of hypertension at 
baseline in subjects who became dcmented, resulting in a potential 
overestimation of the protective cffect. However, it is not common practice to 
stop antihypeltensivc treatment, and we consider it unlikely that this kind of 
misclassification has affected our results. 
In a Shldy on the effects of antihypertensives on dementia confounding by 
indication is an important issue as there is evidence that long-standing 
hypertension could lead to dementia. 1-4 It is conceivable that physicians tend to 
prescribe less antihypertensives to subjects with pre-clinical symptoms of 
dementia because of fear of diminishing brain perfusion or because of expected 
inappropriate use. Although we tried to minimize this problem by adjusting for a 
number of putative confounders and the exclusion of subjects demented within I 
year from baseline, we can not exclude the possibility that there may be some 
residual confounding. However, residual confounding would probably have led 
us to underestimating the effect of antihypertensives in dementia. TIlls could 
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explain the lack of a statistically significant cffect in AD but not the observed 
risk reduction in YD. An alternative explanation for finding no significant effect 
in AD may be the lack of power at the relative risk that we observed, in 
pmticular for the stratified analyses. We calculated that the minimal overall risk 
reduction that we could find was approximately 40% given a power of 80% and 
an alpha of 5%. 
Subjects with missing values in continuous variables were excluded. 
Although these subjects were more often users of antihypeltensives lise and had 
a higher incidence of dementia, we think that this was mainly a consequence of 
higher age. Even when the missing-status was associated with a higher chance of 
getting dementia it is unlikely that this was differential between users and non-
users of antihypertensive drugs. 
A final problem may be the phenomenon of competing risk. This is an event 
that removes a subject from being at risk for dementia. The most important 
competing event in our study seems death. However, as the adjusted death rate 
in treated subjects was not significantly higher than in untreated subjects with 
high blood pressure this makes it less likely as an explanation for our findings. 
Given the existing evidence how should our study be valucd? In contrast to the 
Syst-Eur trial" and the Kungsholmen study' we did not find a significantly 
reduced risk of demcntia. However, although not significant, in the overall 
analyses we found a risk reduction of approximately 30%, which equals the 
reduction found in the Kungsholmen Shldy. The most plausible explanation for 
the lack of significance in our study is the higher mean age in the Kungsholmen 
Study leading to a higher exposure prevalence and higher incidence of dementia. 
Although it is known that treatment of hypertension reduces associated 
morbidity, to our knowledge no prior study has shown a risk rcduction of 
vascular dementia. Moreover, our results do not indicate that there are harmfhl 
effects with respect to the occurrence of the dementia subtypes they once more 
stress the impOitance of adequate antihypertensive treatment. 
It has been suggested that there are gender differences with respect to 
treatment responsiveness of prevalent dementia to other dl1lgs22 as well as in 
contribution of other risk factors. In our study in incident demented there was 
also evidence for a difference, although confidence intervals overlapped. With 
respect to these gender differences it is unclear whether they are real and if so 
whether they are attributable to preferential prescribing of certain drugs, the 
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degree of treatment or the contribution of hypertension to thc development of 
dementia within the sexes. 
In conclusion, we found that antihypertensive medication was associated with 
a lower risk of dementia. Our results were only significant and lllore outspoken 
for vascular dementia, but there was a tendency for antihypertensive medication 
to be associated with lower risks of AD as well. As future placebo controlled 
trials are not likely to be exccuted because of ethical complications, studies with 
longer follow-up, a larger sample of demented subjects and longihldinal 
exposure data are needed to fUlther explore this association. 
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4.1 
Cerebral hemodynamics, cognitive decline and 
dementia in the Rotterdam Study 
Abstract 
Background Transcranial Doppler (TCD) is a noninvasive tool to measure 
cerebral blood flow (CBF) velocity and cerebrovascular CO2 reactivity in 
cerebral arteries. Clinical TCD studies have demonstrated a decrease in blood 
flow velocity in the proximal tract of the middle cerebral artel)' in patients with 
Alzheimer's disease. A reduced cerebrovascular CO2 reactivity, indicating 
cerebral small vessel pathology, has been found in vascular dementia patients. It 
is unclear wether cerebral blood flow velocity and cerebrovascular CO2 
reactivity are decreased il1 persons with cognitive impairment. 
Design/methods We examined the association between cerebral hemodynamics, 
as measured by means of TCD, and dementia and cognitive pelformance in 
2,107 participants of the Rotterdam Study, a large population-based stU(O' in the 
Netherlands. 
Results A total of 18 individuals were diagnosed with deme!ltia. All cerebral 
hemodynamic parameters were lower in demented compared with non-demented 
persons (mean dijJerence end diastolic CBF: 5.7 CIII/sec, 95%CI: 2.0-9.7; peak 
,),stolic CBF: 14.0 cm/sec, 95%CI 5.2-22.8; mean CBF: 8.6 cm/sec, 95%CI: 
3.4-13.8; cerebrovascular COl reactivity: 0.2 %/kPa, 95%CI: -1.1-1.4). Among 
non-demented subjects those who had declined in the period before TCD 
assessment had the lowest CBF velocity and cerebrovascular CO2 reactivity. 
Persons with low cognitive pelformal1ce had a lower cerebrovascular CO2 
reactivity as well. 
Conclusion Our data suggest that cerebral blood flow velocity and 
cerebrovascular CO2 reactivity are decreased in persons with dementia and are 
lower in persons with impaired cognitive pelformance. 
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Introduction 
Transcranial Doppler ultrasonography (TCD) is a noninvasive tool to measure 
cerebral blood flow velocity in cerebral arteries 1 Neuroradiologic techniques 
including SPECT and PET have shown reductions of global and regional 
cerebral blood flow in patients with Alzheimer's disease?, 3 Furthermore, a 
decrease in blood flow velocity in the proximal tract of the middle cerebral 
altelY in Alzheimer patients has been demonstrated in clinical TCD studies.4-8 
This association has not been examined in the general population. An abnormal 
cerebral blood flow and impaired vascular response to metabolic demand, 
indicating cerebral small vessel pathology,9 have been observed in vascular 
dementia lO, II It is unclear whether cerebral blood flow and cerebrovascular 
CO, reactivity are already decreased in persons with cognitive impairment who 
are not demented. 
In this study, we examined the association between cerebral hemodynamics 
(including cerebral blood flow velocity and cerebrovascular CO, reactivity), 
measured by means of TCD, and cognitive decline and dementia, within the 
Rotterdam Study, a large population based study in the Netherlands. 
Methods 
Study population 
The study is based on the Rotterdam Shldy, a population based prospective 
cohort study that is ongoing since 1990. 12 TCD assessment was added to the 
core protocol for the second re-examination (1997-1999), in which 4,730 
persons participated. Of these, 4,214 visited the shldy research centre. In 1,113 
participants we were unable to perform TCD due to logistic reasons (no research 
assistant available). Adequate transcranial Doppler data were obtained in 2,107 
of the 3,101 participants (67.9 %) in whom we tried to assess cerebral blood 
flow velocity and cerebrovascular CO, reactivity. The other 994 participants had 
window failure on both sides (n ~ 769), difficulty to participate due to 
restlessness or discomfort (n ~ 38) or data were lacking due to other reasons (n ~ 
187). 
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Tl'Onscl'Onial Doppler Assessment 
Transcranial Doppler ultrasonography monitoring was performed (Multi-Dop X-
4, OWL, Sipplingen, Germany) and the cerebral blood flow velocity (cm/sec) 
was mcasured in the middle cerebral artcty on both sides if possible. End 
diastolic, peak systolic and mean cerebral blood flow velocities were recorded 
automatically. Cerebrovascular CO2 reactivity measurements were done as 
follows. The cerebral blood flow velocity in the middle cerebral artety was 
mcasured continuously and thc participants first breathed room air through an 
anaesthetic mask, tightly fit over mouth and nose, until a steady expiratory end-
tidal CO2 was obtained. Participants were then asked to inhale a mixturc of 5% 
carbon dioxide in 95% oxygen for two minutes. Ccrcbrovascular CO2 was 
dcfincd as the percentage increase in cerebral blood flow velocity occurring 
during inspiration of 5% CO2, divided by the absolute increase in end-tidal CO2 
in the same period (%/kPa). End-tidal CO2 pressure (kPa) was recorded 
continuously with a CO2 analyser (Muitinex, Datascope, Hoevelaken, The 
Netherlands). End-expiratory CO2 was assumed to reflect arterial CO2,l3 TCD-8 
DWL special software (VMR-CO,) was used. All transcranial Doppler data were 
stored on hard disk for off-line analysis. 
Diagnosis of dementia 
Dementia scrccning and diagnosis followed a three-step protocol, as described in 
detail elsewhere. 14 Briefly, all subjects were screened with a short test of 
cognition (Mini Mental State Examination (MMSE)15 and the Geriatric Mcntal 
State schedulc, organic leveP6). Screen positives underwent further cognitive 
testing, and an informant interview was obtained. Persons suspected of dementia 
were examined by a neurologist and underwent more elaborate 
neuropsychological testing. If possible an axial Tl, T2 and coronal T I cerebral 
MRI scan was made in order to assess hippocampal and cortical atrophy and to 
exclude other causes of dementia. Dementia diagnosis was made according to 
internationally accepted criteria (NINCDS-ADRDA, NINDS-AIREN, DSM-III-
R) by a panel that reviewed all existing infot111ation. 14, 17-19 
lvleasllrements of cognitive /tlllction 
As part of the cognitive assessment the following neuropsychological tests were 
administered: the Dutch version of the 3D-point Mini Mental State 
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Examination;i5 an abbreviated Stroop test consisting of three subtasks20 (in Part 
1, the subject reads color names printed in black ink, in Pmt 2, the subject has to 
name the color of squares, in Part 3, the subject has to name the color in which 
the color names are printed and disregard their verbal content2l); the Letter Digit 
Substitution Task, which is a modified version of the Symbol Digit Modalities 
Test;22 and a verbal fluency test in which as many animals as possible had to be 
named within 60 seconds. The MMSE is a global cognitive test developed to use 
in dementia screening l5 and appeals mainly to cOltical fimctions. The Stroop test 
and verbal fluency test are timed tasks that measure executive control functions 
(mental flexibility, vulnerability to interference, concept shifting), sustained 
attention and mental speed. The Letter Digit Substitution Task is used to assess 
complex scanning and visual tracking.22 
The MMSE had been administered during previous examination rounds 
(1990-1993; 1993-1994) of the Rotterdam Study and the Rotterdam Scan study 
(1995-1996)23 as well. Therefore, we were able to examine cognitive decline in 
the period preceding the TCD assessment (on average 6.5 years). We assumed a 
linear decline over time and calculated the rate of decline in MMSE for all 
participants with at least two measurements (n ~ 3,062) and who were still non-
demented at time of the last MMSE measurement. 
Data analysis 
We used the mean of right and left hemodynamic parameters for the analyses if 
both middle cerebral arteries could be insonated adequately. In case of one-sided 
window-failure, the contralateral cerebral hemodynamic parameter was used in 
the analyses. Differences in characteristics between persons with successful 
TCD measurements (n ~ 2,107) and without suecessfiIi TCD measurements (n ~ 
994) were compared using analysis of covariance adjusted for age and gender. 
To assess the relation between hemodynamic parameters and cognitive 
fimetion and dementia, we first compared these parameters between demented 
and non-demented persons. Next, we investigated within non-demented persons 
the cross-sectional relation between cerebral blood flow velocity and 
cerebrovascular CO, reactivity and cognitive test scores. Finally, we compared 
within non-demented persons the hemodynamic parameters between those who 
had declined on the MMSE in the preceding period and those who had not. 
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The relation between cerebral hemodynamic parameters and dementia was 
asscssed by analysis of covariance and by logistic regression analysis where we 
used hemodynamic parameters as the determinant and dementia as outcome. The 
relation between cerebral hemodynamic parameters and neuropsychological test 
performance was assessed by means of multivariate regression. 
Neuropsychological test results were available on more than 99% of the subjects 
in tIus study. If data were missing because the person was cognitively unable to 
complete thc test, rather than cxcluding him or her fi'Om the analyses, we 
assigned that person the worst score that was obtained among those who did 
complete the tests. Otherwise subjects were excluded from that particular 
analysis. The relation between hemodynamic parameters and cogtutive decline 
was assessed by analyses of covariance and by logistic regression analysis. 
Individual rates of decline in MMSE scores were calculated based on at least 
two and maximal five MMSE scores with the use of a random effects model 
(SAS 6.12, PROC MIXED). We used all baseline and follow-up MMSE-
mcasurements as outcome variable, time of measurement as independent 
variable with time at baseline exanunation as t~O, and the intercept and time of 
MMSE measurement as random effects. The estimated fixed effect and the 
individual random effect were added to obtain the estimated slopes and 
intercepts of the individual MMSE scores. We defined cog1utive decline as a 
decline of more than two standard deviations from the mean decline of the total 
non-demented population (0.20 points per year). All analyses were adjusted for 
age and gender. Additional adjustments were made for education, dichotomised 
in primaty education or less and more than primaty education. 
Table 1. Characteristics of participants ill the study population with and without transcranial Doppler (TCD) 
examinations. 
Age (yrs) 
Gender (%women) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Primary education or less (%) 
TCD* 
(n ~ 2.107) 
71.2 (6.5) 
46.7 
142.9 (20.8) 
75.4 {I 1.2) 
25.1 
Dementia (%) 0.9 
* Values represent means (SO) 
t Adjusted difference adjusted for age and gender 
No TCD* 
(n ~ 994) 
73.6 (6.7) 
78.2 
145.7 (21.7) 
75.1 (11.1) 
34.3 
1.7 
Adjusted difl'erencet 
(95% el) 
2.4 (1.9;2.9) 
31.6 (28.0;35.2) 
1.8 (0.2;3.5) 
0.8 (-O.O; I. 7) 
1.9 (-1.6;5.5) 
0.4 (-0.5;1.2) 
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Results 
Table 1 shows the characteristics of participants with and without adequate TCD 
measurements. Subjects without TCD measurements were on average older, 
more frequently female and had a higher systolic blood pressurc compared to 
those with TCD measurements. 
Of the 18 demented with TCD assessment (9 men and 9 women) 16 were 
diagnosed with Alzheimer's disease and 2 with vascular dementia. Dementia 
patients had either minimal (n = 12, Clinical Dementia Rating Scale = 1) or mild 
dementia (n = 6, Clinical Dcmentia Rating Scale = 2).24 In 11 of the 18 dementia 
patients (61 %) we obtained MRI (9 Alzheimer's disease, 2 vascular dementia). 
Of the Alzheimer patients, 7 had moderate to severe atrophy and 2 patients had 
normal scans. Besides the atrophy, 3 patients had also mild white matter lesions. 
Table 2. Comparison of cerebral hemodynamic pllramclers in persons ,,,ilh and without dementia. 
No dementia* Dementia* Adjusted Odds ratiat 
(n ~ 2,089) (n ~ 18) diflerencet (95% el) 
(95% el) 
End diastolic CBF vclocity (em/s) 32.5 (9.0) 22.0 (5.7) 5.7 (2.0;9.7) 0.31 (0.15-0.61) 
Peak systolic CDF velocity (em/s) 86.5 (19.0) 70.0(16.1) 14.0 (5.2;22.8) 0.62 (0.46-0.83) 
r.,'[ean CBF velocity (em/s) 50.5 (11.6) 38.0 (8.6) 8.6 (3.4;13.8) 0.40 (0.24-0.68) 
Cerebrovascular CO2 reactivity (%!kPa) 3.9 (2.6) 2.9 (2.4) 0.2 (-1.1 ;1.4) 0.97 (0.76-1.22) 
*Values represent means (SD) 
tAdjusted difference (95% el), adjusted for age and gender 
!Odds ratio (95% el), adjusted for age and gender, per 10 cm/s increase in cerebral blood flow velocity 
CBF = cerebral blood flow 
Cerebral blood flow velocity was significantly lower in demented than in non-
demented persons (Table 2). Cerebrovascular CO, reactivity was lower in 
demented than in non-demented participants, but the difference was not 
statistically significant. When we repeated these analyses confined to patients 
with Alzheimer's disease, the results were virtually the same as for all dementia 
patients. 
Non-demented participants with higher cerebral blood flow and 
cerebrovascular CO, reactivity tended to perform better on cognitive tests (Table 
3). Additional adjustment for education did not essentially change the results. 
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Table 3. Adjusted difference in test score by increasing cerebral blood flow velocity (per 10 cmlsec) and by increasing 
cerebrovascular CO, reactivity (per %lkPa)*. 
StrOOI! (sec) Letter Digit 
W ordflucncy Substitution Task 
Part 2 Part 3 Part (3·2) MMSE (animals/min) (letters/min) 
Mean neuropsychological test result (SD) 24.5 (5.4) 62.5 (40.2) 38.1 (38.5) 27.9 (1.7) 21.4 (5.4) 27.6 (6.8) 
Cerebral blood flow velocity (per 10 em/s) 
End diastolic -0.34(-0.61;·0.07) 0.51 (-2.50;1.51) ·0.17 (-2.12;1.77) 0.03 (-0.05;0.12) 0.14 (-0.13;0.41) 0.06 (-0.27;0.39) 
Peak systolic -0.12 (·0.24;0.00) 0.08 (-0.82;0.98) 0.20 (-0.67;1.07) 0.01 (-0.03;0.04) 0.02 (·0.10;0.13) 0.05 (-0.09;0.20) 
Mean -0.24 (-0.44;-0.04) ·0.12 (-1.63;1.40) 0.12 (·1.34;1.58) 0.02 (-0.05;0.08) 0.07 (-0.13;0.27) 0.07 (-0.17;0.32) 
Cerebrovascular CO2 reactivity (per %lk.Pa) ·0.04 (·0.13;0.05) 0.14 (-0.53;0.81) 0.18 (-0.45;0.83) 0.05 (0.02;0.07) 0.12 (0.03;0.20) 0.19 (0.08;0.29) 
"'Regression coefficient and 95% CI. adjusted for age and gender 
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Table 4 shows the comparison of blood flow velocities and cerebrovascular CO, 
reactivity betwcen participants with and without cognitive decline in the period 
preceding TCD assessmcnt. Persons with cognitive decline had lower cerebral 
blood flow velocities compared to those without cognitive decline. Mean 
cerebrovascular CO, reactivity was also lower in persons with than without 
cognitive dccline (cerebrovascular CO, reactivity: 0.8 %/kPa; 95% CI: 0.2-1.4). 
Additional adjustment for education level did not change the results. 
Table 4. Comparison of cerebral hemodynamic parameters in persons with and without cognitive dec1ine*. 
No cognitive Cognitive Adjusted Odds ratiot 
decline' dccIinc~ diffe-fencer (95% CI) 
(ll ~ 2,008) (ll ~ 81) ( 95% CI) 
End diastolic CBF velocity (em/s) 32.6 (9.0) 29.2 (8.6) 0.73 (0.55·0.97) 0.73 (0.55·0.97) 
Peak systolic CBF velocity (em/s) 
~\!lcan CBF velocity (em/s) 
86.7 (18.9) 
50.6 (1\.5) 
80.6 (18.6) 0.85 (0.75·0.97) 0.85 (0.75·0.97) 
46.3 (11.2) 0.77 (0.62-0.95) 0.77 (0.62-0.95) 
Cerebrovascular COl reactivity (%/kPa) 3.9 (2.7) 2.9 (1.8) 0.86 (0.76-0.96) 0.86 (0.76-0.96) 
*Cognitivc decline defIned as a decline of more than two standard deviations from the mean decline oflhe 
non-demented population 
'Values represent means (SD) 
tAdjustcd difference (95% CI), adjusted for age and gender 
tOdds ratio (95% CI), adjusted for age and gender, per 10 cm/s increase in cerebral blood flow velocity 
CBF = cerebral blood flow 
Discussion 
We found in a large population-based study that cerebral blood flow velocity 
was not only significantly lower in persons with dementia, but also in non-
demented persons with cognitive decline as compared to cognitively intact 
subjects. Likewise, the cerebrovascular CO, reactivity was significantly lower in 
persons with cognitivc decline and in those with impaired cognitive performance 
and tended to be lower in dementia patients. 
Before further discussing our findings we want to consider whether selection 
bias may have influenced our findings. First, since participants had to attend the 
research centre for TCD asscssment, persons with severe dementia and persons 
with severe comorbidity are underrepresented in our study sample. The 
relatively healthy sample in our study may have attenuated the strength of the 
associations. Second, TCD was not assessed in 26 percent of all persons visiting 
the research centre. Howevcr, sincc this was a random sample of all eligible 
persons that visited the research centre it is unlikely that this has biascd our 
70 
Transcranial Doppler and dementia 
results. Third, we failed to obtain adequate TCD data in 32 percent of 
participants in whom we tried to assess hemodynamic parameters, mainly duc to 
window failure. Tlus rate is in accordance with previous fmdings from clinical 
studics.25, 26 This could have biased our results if window failure were related to 
cogtutivc performance or dementia, wluch wc consider unlikely. 
To our knowledge, this is the first population-bascd study examining cerebral 
hemodynamic parameters in relation to dementia and cogtutive decline. Some 
small, clinical studies suggested no differences in basal flow velocities between 
healthy controls and Alzheimer patients and lower flow velocities and 
diminished vasomotor responses in multi-infarct dementia patients.6, 11 It should 
be noted that these studies used highly selected Alzheimer patients to exclude 
confounding by vascular pathology. In our study, we were unable to evaluate 
differences between Alzheimer's disease and vascular dementia since we had 
only two vascular demcntia patients in our sample. 
The explanation for our finding that cerebral blood flow velocity is lower in 
dementia patients and persons with cognitive dysfunction compared to non-
demented persons is still unclear. The reduced flow velocities may represent 
consequences of reduced metabolic needs due to neuronal tissue loss.26, 27 
Neuroradiologic techniques including SPECT and PET have shown reductions 
of global and regional cerebral blood flow in subjects with Alzheimer's 
disease?, 3, 8, 26 Flow abnormalities in persons with vety mild dementia have also 
been found'? An alternative explanation is that a decline in cerebral blood flow 
velocity is a risk factor for dementia. A decrease in blood flow velocity results in 
decreased delivety of oxygen.28 Hypoxia may affect cognitive function29 and 
may cause ischaemic neuronal lesions in vulnerable areas of the brain,30 
especially in watershed areas. 30, 31 Our observation that cerebral blood flow 
velocity was ah'eady lower in persons with cognitive decline, without dementia, 
docs fit with both explanations. Follow-up studies with repeated assessments are 
needed to distinguish between these mechatusms. 
Transcratual Doppler ultrasonography is one of the safest and most 
inexpensive as well as the most reliable techniques to evaluate cerebral arterial 
reserve capacity.32 A low vasomotor response may indicate small vessel 
pathology.9 In our study, cerebrovascular CO, reactivity was lower in persons 
with cognitive decline or low cognitive performance, lending further support to 
the hypothesis of a role for vascular risk factors and vascular disease in the 
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aetiology of cognitive decline and dementia. The fact that we did not find a 
significantly lower cerebrovascular CO2 reactivity in persons with dementia may 
reflect lack of power. However, it is also possible that this was a group of 
relatively healthy and 'pure' Alzheimcr patients who were free of vascular 
comorbity. 
In conclusion, our study demonstrates that cerebral blood flow velocity is 
significantly lower in persons with dementia and cognitive decline than in 
persons with intact cognition. Also, cerebrovascular CO, reactivity was lower in 
persons with reduced cognitivc function. Whether the lower blood flow velocity 
and vasomotor response are a cause or a consequence of dementia remains to be 
elucidated. Future research should include more non-invasive diagnostic tools to 
investigate cerebral hemodynamics, such as transcranial Doppler. 
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Atherosclerosis and the risk of dementia 
and Alzheimer's disease in a 6-years follow-up 
study: the Rotterdam Study 
Abstract 
Background Evidence is accumulating that vascular disorders are implicated in 
dementia and its 1II0stji-equent subtype, Alzheimer's disease. In an earlier report 
.!i·om the Rotterdam Study we showed that the prevalence of dementia, 
Alzheimer's disease and vascular dementia increased with the degree of 
atherosclerosis. Here we report a 6-years prospective follow-up study of 
atherosclerosis and the incidence of dementia and its subtypes. 
Methods We examined the relation between atherosclerosis and risk of 
dementia in the Rotterdam Study, a prospective population-based study of 7,983 
subjects aged 55 years and over. Indicators of atherosclerosis included wall-
thickness and plaques of the carotid arteries, as assessed by ultrasonography, 
and systolic blood pressure ankle-to-brachial index, as a measure of generalised 
atherosclerosis. From these indicators a score of atherosclerosis ranging ji-om 0 
(no atherosclerosis) to 3 (severe atherosclerosis), was constl'llcted. 
Findiugs After a mean follow-up of 5.7 years, 395 nell' cases of dementia were 
identified. Of 6,142 persons (309 cases) of the total cohort at risk of developing 
dementia, il?formationwas available on at least one indicator of atherosclerosis. 
Wall thickness of the common carotid arteries and presence of plaques in the 
carotid arteries were significantly associated with all demelllia and Alzheimer's 
disease. The relative risks of all dementia, Alzheimer's disease and vascular 
dementia increased by the score of atherosclerosis (severe atherosclerosis 
compared to no atherosclerosis: all dementia: RR 1.58; 95% CI: 1.02-2.44; 
Alzheimer's disease: RR 1.76, 1.07-2.89; vascular dementia: RR 1.62, 0.55-
4.77). 
Interpretation Our findings suggest that atherosclerosis is associated not only 
with a small group of vascular dementia, but also with the major subtype of 
dementia, Alzheimer's disease. 
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Introduction 
Evidence is accumulating that vascular disorders are implicated in dementia and 
its most frequent subtype, Alzheimer's disease. I, 2 Atherosclerosis has also been 
linked to dementia, and we previously repOited that various indicators of 
athcrosclerosis are associated with prevalent dementia.3 
Here we report a 6-years prospective follow-up study of atherosclerosis and 
the incidence of dementia and its subtypes in 395 new cases of dementia 
identified in 7,046 participants at risk for dementia. 
Methods 
Stltdy design 
The Rotterdam Study is a population based prospective cohOlt Shldy among 
7,983 persons aged 55 years and older living in a suburb of Rotterdam, the 
Netherlands. The objective of thc Shldy is to investigate determinants of chronic 
and disabling diseases.4 The Shldy has been approved by the Medical Ethics 
Committee of the Erasmus University. Participants gave written informed 
consent and permission to retrieve information from treating physicians. 
Baseline examinations took place between 1990 and 1993. Participants were 
interviewed at their homes and thereafter, during two sessions, examined at the 
research centre. At baseline, 7,528 persons (94.3% of total cohort) underwent 
extensive screening for dementia5 and 482 persons were identified with 
prevalent dementia. This resulted in a cohort of 7,046 participants at risk for 
dementia. The cohOlt was re-examined in 1993-1994 and in 1997-1999. 
Diagnosis of dementia 
Dementia screening and diagnosis during baseline and follow-up examinations 
were similar.5 Briefly, all subjects were screened with a short test of cognition 
(Mini Mental State Examination6 and the Geriatric Mental State schedule, 
organic leveF). Screen positives underwent further cognitive testing, and an 
informant interview was obtained, Persons suspected of dementia were 
examined by a neurologist and underwent neuropsychological testing, To 
differentiate vascular dementia from Alzheimer's disease a brain scan was made 
by magnetic resonance imaging (MRJ) or computed tomography (CT). In 
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addition to dementia screening in person, the total cohort is continuously being 
monitored for detection of interval cases of dementia by means of computerised 
linkage of the study database with general practitioners medical records and the 
database of the Regional Institute for Outpatient Mental Health Care (RIAGG).5 
Of both the in-person-screened individuals and those monitored through general 
practitioners and mental health services, a diagnosis of dementia was made 
according to established criteria (NINCDS-ADRDA, NINDS-AIREN, DSM-IlI-
R) by a panel that reviewed all existing information.5, 8·[0 
lvJeasurements of atherosclerosis and other baseline measurements 
Presence of atherosclerosis of the carotid arteries (wall thickness and plaques as 
measured by ultra-sonography) and presence of atherosclerosis of the large 
vessels of the legs (assessed by the ratio of the ankle-to-brachial systolic blood 
pressure) were assessed as potential risk factors for dementia. 
Ultrasonography of both carotid arteries was performed with a 7.5 MHz 
linear-alTay transducer and a duplex scanner (A TL UltraMark IV, Advanced 
Technology Laboratories, Bethel, W A). Intima-media thickness was measured in 
the common carotid arteries as described previously 1 I Presence of 
atherosclerotic plaques, defined as a focal widening relative to adjacent 
segments with protrusion into the lumen, was assessed in the common carotid 
arteries, the bifurcation and the internal carotid arteries. I2 The presence of 
atherosclerosis of the lower extremities was non-invasivcly assessed with the use 
of ultrasound. The ratio of the ankle-to-brachial systolic blood pressure (ankle-
to-brachial index) reflects the presence of atherosclerotic vessel wall 
abnormalities of the arteries of the lower extremities and has been shown to be a 
good indicator of generalised atherosclerosis.I3, 14 Ankle systolic blood pressure 
was determined with the subject in supine position at both right and left posterior 
tibial arteries using a Doppler ultrasound transducer with a random-zero 
sphygmomanometer (cuff-size 38 x 14 cm). The average of the left and the right 
ankle-brachial index was used in the present analyses. Peripheral arterial disease 
was considered present when left or right ankle-brachial index was less than 
0.90. 
Baseline blood pressure was measured in sitting position at the right upper 
arm with a random-zero sphygmomanometer. The average of two 
measurements, separated by a count of the pulse rate, was used. Apolipoprotein-
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E (APOE) genotyping was performed on coded DNA samples without 
knowledge of the diagnosis. The polymerase chain reaction product was digested 
with the restriction enzyme Hha!, and fragments were separated by 
electrophoresis. IS Serum total and high-density lipoprotein (HDL) cholesterol 
concentrations were detennined by an automated enzymatic procedure. 16 Body 
mass index was determined as body weight (in kg) divided by height squared (in 
m'). Smoking was categorised as never, fonner and current smoking. 
Statistical analysis 
The associations between atherosclerosis, and dementia, Alzheimer's disease and 
vascular dementia were analysed as follows. First, the relative risks of dementia 
associated with indicators of atherosclerosis were calculated with Cox' 
proportional hazards regression and presented with a 95% confidence interval 
(95% CI), controlling for age, age', and gender. 
Second, a composite measure of atherosclerosis was constructed: a point was 
added to the atherosclerosis score if the following characteristics were present: 
plaques in at least three locations of carotid arteries (left or right bifurcation, left 
or right internal- or common carotid arteries), average wall-thickness of COnl1110n 
carotid arteries in the highest quintile of the distribution, and evidence of 
peripheral arterial disease, defmed as ankle-to-brachial index less than 0.90. The 
cut-off points for indicators of atherosclerosis were selected approximately 
according the upper quintile of the distribution. This atherosclerosis score was 
analysed in four categories corresponding to score values of 0-3. With a Cox' 
propOllional hazards model, the relative risk for each category of atherosclerosis 
for dementia and its subtypes was calculated, adjusting for age, age', and gender. 
Third, we investigated possible biological interaction between the 
atherosclerosis score and the apolipoprotein-E polymorphism.!7 To investigate 
the combined effect of APOE and atherosclerosis, the Shldy population was 
dichotomised according to atherosclerosis score, and classified into four groups: 
(I) APOE3E3 carriers with an atherosclerosis score of 0 or I (reference group); 
(2) Carriers of APOE*4 with an atherosclerosis score of 0 or I; (3) APOE3E3 
carriers with an atherosclerosis score of 2 or 3; (4) APOE*4 cal1'iers with an 
atherosclerosis score of 2 or. 
No major differences in the association between atherosclerosis and dementia 
were observed between men and women, and therefore the estimates are 
78 
Atherosclerosis and dementia 
presented for men and women combined. These associations were virtually not 
altered after adjustment for blood pressure, total cholesterol and body mass 
index, and therefore presented with adjustments for age, age' and gender. 
Results 
In Table I characteristics of the study population are summarised. After a mean 
follow-up of 5.7 years, 395 new cases of dementia were identified. Alzheimer's 
disease was diagnosed in 293 (74%) persons and vascular dementia was 
diagnosed in 57 (14%) persons. Of 6,142 pcrsons (309 cases) of the total cohort 
at risk of developing demcntia, infol1nation was available on at least one 
indicator of atherosclerosis. The percentage of missing values was 13% for 
peripheral arterial disease, 36% for wall thickness of common carotid atteries, 
23% for plaques in carotid arteries and because this was a composite score 46% 
for the atherosclerosis score. Persons wi thout measurements were on average 
older, but did not significantly differ in gender distribution or dementia 
incidence. 
Table 1. Baseline characteristics of tile study population. 
lIvlen 
Age (years) 68.3 (55·96)' 
Systolic blood pressure (rum Hg) 
Diastolic blood pressure (mm Hg) 
Total cholesterol (mmollL) 
Body Mass Index (kglm2) 
Smoking (%) 
Never smoked 
Smoked in the past 
Current smoker 
138.7 (21.7) 
74.5 (11.5) 
6.3(1.1) 
25.7 (3.7) 
8.2 
61.9 
29.9 
Women 
70.3 (55·106) 
139.8 (22.6) 
73.2 (11.4) 
6.8 (1.2) 
26.8 (4.1) 
54.2 
27.8 
18.1 
Total Population 
69.5 (55·106) 
139.3 (22.3) 
73.6 (11.5) 
6.6 (1.2) 
26.3 (4.0) 
35.6 
41.6 
22.8 
'Values represent means and ranges for age, and means and standard deviations for other variables. 
Wall thickness of the common carotid arteries and presence of plaques in the 
carotid atteries were significantly associated with all dementia and Alzheimer's 
disease (Table 2). The relative risks of all dcmentia, Alzheimcr's disease and 
vascular dcmentia increased by the score of atherosclerosis (Table 3). 
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Table 2. Relative risk of Alzheimers disease. vascular dementia and total dementia with indicators of atherosclerosis' 
Peripheral arterial disease 
Wall thickness cornmon carotid artcrics+ 
Wall thickness common carotid arteries. 
highest quintilc versus lower quintilcs 
Plaque in bifurcation: no plaques 
plaque either in left or right 
plaque present in both 
Plaque in internal carotid arteries 
no plaques 
plaque either in left or right 
plaque prescnt in both 
Plaque in common carotid arteries 
no plaques 
plaque either in left or right 
plaque present in both 
Plaques in carotid arteries dichotomised in less than 
three locations versus more than three locations 
• Adjusted for age. agc~ and gender 
1"Relative risk of one SD (0.22 nun) increase of wall thickncs 
Alzheimer's disease 
1.14 (0.85-1.53) 
!.16 (1.01-1.32) 
1.26 (0.92-1.73) 
1.0 
1.08 (0.74-1.56) 
1.12 (0.78-1.60) 
1.0 
1.27 (0.88·1.82) 
1.41 (0.97·2.05) 
1.0 
0.89 (0.58-1.38) 
1.59 (1.00-2.52) 
1.36 (1.02-1.82) 
Vascular dementia All dementia 
1.31 (0.70-2.45) !.13 (0.87-1.45) 
1.20 (0.93-1.57) !.II (1.00-1.26) 
1.43 (0.76-2.71) 1.17 (0.89-1.53) 
1.0 1.0 
1.28 (0.58-2.85) !.l4 (0.83-1.57) 
1.33 (0.62-2.84) 1.21 (0.89-1.64) 
1.0 1.0 
0.42 (0.14-1.23) !.l4 (0.84-1.57) 
1.75 (0.88-3.49) 1.37 (1.00-1.89) 
1.0 1.0 
0.74 (0.29-1.89) 0.80 (0.54-!.l7) 
1.45 (0.56-3.74) 1.41 (0.94-2.11) 
1.51 (0.83-2.74) 1.32 (1.03-1.68) 
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Table 3, Relatiye risk of Alzheimer's disease, yascular dementia and total dementia with indicators of 
atherosclerosis*' . 
Alzheimer's diseasc Vascular demcntia All dcmentia 
(n = number of cases) (n ~ 151) (n ~ 35) (n ~ 208) 
Atherosclerosis score 1.0 1.0 1.0 
0.74 (0.48-1.13) 0.59 (0.22-1.60) 0.77 (0.54-1.10) 
1.24 (0.79-1.96) 1.92 (0.81-4.52) 1.24 (0.84-1.82) 
1.76 (1.07-2.89) 1.62 (0.55-4.77) 1.58 (1.02-2.44) 
p-yalue for trend p = 0.04 P ~ 0.07 p ~0.03 
*' Adjusted for age, age2 and gender 
Persons with evidence for atherosclerosis (score 2 or 3) and the APOE*4 
genotype had an increased risk of all dementia (RR 3.1,95% CI: 2.4-5.9), of 
Alzheimer's disease (RR 4.1, 95% CI: 2.4-6.8), and of vascular dementia (RR 
4.7,95% CI: 1.5-14.5)(Table 4). 
Table 4. Relativc risk of Alzhcimer's disease, vascular dementia and total dementia by atherosclerosis and 
apoliQoprotein gen0!YEe*'. 
Genotypet Alzheimer's diseasc Vascular dementia All dcmcntia 
Atherosclerosis Atherosclerosis Atherosclerosis 
+ + + 
ApoE 33 1.0 1.93 1.0 2.17 1.0 1.80 
(reference) (1.17-3.18) (refcrence) (0.80-5.90) (reference) (l.l7-2.77) 
ApoE4+ 2.65 4.05 2.89 4.71 2.72 3.71 
(1.73-4.07) (2.40-6.81) (1.13-7.37) (1.53-14.51) (1.89-3.91) (2.35-5.86) 
* Adjusted for age, age2 and gcnder 
tApoE 33: apolipoprolein-E £3/£3 genotype; ApoE 4+: apolipoprotcin-E £2/£4, £3/£4, or £4/£4 
Discussion 
The main finding of this study is that indicators of atherosclerosis are associated 
with the risk of dcmentia and both of its main subtypes, Alzheimer's disease and 
vascular dementia. Some limitations of our study have to be discussed. 
It is likely that some error has occurred in the measurement of atherosclerosis 
indicators. Such cnor would have led to misclassification and to underestimation 
of any tme association between atherosclerosis and demcntia, provided that the 
measurement error occurred to the same extent among the dementia patients and 
the non-demented participants. We used ultrasonographic indicators of 
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athcrosclerosis, but incrcased thickness of the intima media wall of the common 
carotid artelY may not necessarily reflect atherosclerosis. Another concern is 
how dementia and its subtypes are diagnosed. Our study used diagnostic 
procedures with relative high sensitivity and specificity through a three-phasc 
diagnostic work_up.5,18,19 Without confirmation at necropsy, however, subtyping 
of dementia rcmains unreliable. In a main analysis, we classified primmy 
Alzheimer's disease, complicated by cerebrovascular disease, as Alzheimer's 
disease. Hqwever, an additional analysis in which cerebrovascular patients were 
excludcd from the Alzheimer group yielded esscntially the same results as the 
main analysis. Although we can not fully exclude misclassification, we believe 
that this analysis supports thc view that atherosclerosis is associated with 
Alzheimer's disease. 
Atherosclerosis may be related to dementia in several ways. Firstly, 
atherosclerosis may cause hemodynamic changes leading to neuronal damage in 
vulnerable areas of the brain. Also, atherosclerosis may impair the blood-brain 
barrier function as a result of cerebral vessel wall damage.2o Finally, vascular 
damage associated with atherosclerosis superimposed on ah'eady existing 
Alzheimer pathology may lead to an earlier detcction of otherwise subclinical 
Alzheimer's disease. 
Our findings suggest that atherosclerosis is associated not only with a small 
group of vascular dementia, but also with the major subtype of dementia, 
Alzheimer's disease. The magnitude of the association is gencrally smaller than 
we have reported bcfore in our prevalence study.3 The attenuation of the 
magnitude of the association may be due to measurement error, as discussed 
before, or to the generally obselved decrease of associations with age. 
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4.3 
Alcohol consumption and risk of dementia: 
the Rotterdam Study 
Background Light-to-moderate alcohol consumption reduces the risk of 
coronOl), heart disease and stroke. Because vascular disease ma), be associated 
with cognitive impairment and dementia, alcohol consumption may also affect 
the risk of dementia. 
Methods We examined the relation between alcohol consumption and risk of 
dementia in the Rotterdam StucO', a prospective population-based study of 7,983 
subjects aged 55 years and over. The stl/dy population consisted of all subjects 
who were non-demented at baseline (1990-1993) and had complete data on 
alcohol consumption (n=5, 395). We used proportional hazards regression 
analysis, ac(justed for age, gender, systolic blood pressure, total cholesterol, 
education, smoking and bocO' mass index. The reference categol)' ineluded 
individuals who did not consullle alcohol. 
Results The average follow-up was 6.0 years. During this period 197 subjects 
developed dementia (J 46 Alzheimer's disease, 29 vascular dementia, 22 other 
dementia). illean alcohol consumption was 0.87 glasses pel' day. Light-to-
moderate drinking (J to 3 glasses!da)~ was significantly associated with a lower 
risk of dementia (relative risk 0.58, 95% confidence inten'al: 0.38-0.90) and 
vascular dementia (relative risk 0.29, 95% cOllfidence interval: 0.09-0.93) and 
diminished the ~tJect of APOE*4 on the risk of dementia. The relation between 
alcohol and dementia did not VOl)' by fJ'lJe of alcoholic beverage. 
Conclusions These findings are compatible with the view that light-to-moderate 
alcohol consulllptionlllay lower the risk of dementia in an elderly population. 
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Introduction 
Light-to-moderate alcohol consumption is associated with lower risks of 
coronaty heatt disease, ischemic stroke and total mortality in elderly men and 
women. I .3 Since evidence is increasing that vascular disease is associated with 
cognitivc impairmcnt and dementia,4.6 light-to-moderate alcohol intake might 
also reduce the risk of dementia and Alzheimer's disease. A population-based 
prospective study in Bordeaux, France reported an inverse association between 
wine consumption and the risk of dementia. 7 We quantified the relation between 
alcohol consumption and the risk of dementia and subtypcs of dementia; 
specifically whether the effect varicd by type of alcoholic beverages. 
Methods 
Study populatioll 
This study was carricd out as patt of the Rotterdam Study, a population based 
prospective CohOlt study for which rcsidents aged 55 years and over of a suburb 
of Rotterdam, the Netherlands, including those living in institutions, were asked 
to participate.8 
During the baseline examination (1990-1993), participants were interviewed 
at home by a trained research assistant. Information was obtained on current and 
past health, medication, lifestyle, and risk indicators for chronic diseases. The 
participants subsequently visited the study center twice for clinical 
examinations. A food-frequency questionnaire was administered to participants 
who attended the second visit at the study center (n = 7,006). The questionnaire 
was not administered during the pilot phase of the Rotterdam Study (n = 273) 
nor to nursing home residents (n = 492). Furthermore, 477 subjects did not 
receive a dietary questionnaire due to logistic reasons. Persons with dementia 
might provide ulll'eliable answers regarding their food pattel11s and therefore the 
questiollnaire was not administered or excluded afterwards (n = 97). For the 
same reason we excluded subjects who were screenpositive (MMSE score below 
26, or a GMS score greater than 0) and scored below 80 points on the 
CAMCOG,9 which is the neuropsychological test administered in the case-
finding procedure for dementia (n = 60). Due to logical inconsistencies in the 
dietary interviews, 212 additional respondents were excluded afterwards, 
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resulting in 5,395 completed reliable questionnaires. Follow-up examinations 
took place in 1993-1994 and in 1997-1999. 
Alcohol intake 
Before the baseline center visits, participants received a checklist on whieh they 
indicated all foods and drinks they consumed at least once during the preceding 
year. The completed checklist fonned the basis of an interview at the study 
center by a trained dietician. An extensive, validated semiquantitative food 
frequency questionnaire was used.lO· II The questionnaire comprised 170 food 
items and all relevant beverages, including tea, coffee, and alcohol. lI The 
reference period was the year preceding the interview. First, subjects were asked 
if they ever drank alcohol. If the answer was affirmative, we asked about the 
frequency of drinking. Persons who reported to drink alcohol at least twice a 
month, were further inquired about average amounts of specific beverages 
(wine, beer, liquor and fortified wine types (e.g. sherry, port)). There were 28 
participants who reported to use alcohol less than twice a month. They did not 
differ from non-drinkers with respect to age, gender, smoking status and 
educational level and were classified as non-drinkers of alcohol. In addition, 
participants were asked if they had changed their pattern of alcohol consumption 
during the preceding five years (less than they used to drink, more than they 
used to drink) and if they had consumed more than six alcoholic beverages on 
one day during the last year (binge drinking). Average daily dietmy nutrient 
intake was calculated by multiplying the frequency and amount consumed for 
each food item by its nutrient content listed in an automated version of the Dutch 
Food Composition Tablel2 
Diagnosis of demel/tia 
Dementia screening and diagnosis during baseline and follow-up examinations 
followed a three-step protocol, as described in detail elsewhere.13 Briefly, all 
subjects were screened with a short test of cognition (Mini Mental State 
Examination l4 and the Geriatric Mental State schedule, organic leveJl5). Screen 
positives underwent fUlther cognitive testing, and an informant was interviewed 
on daily functioning of the pmticipant. Persons who were suspected of dementia 
were examined by a neurologist, underwent neuropsychological testing, and if 
possible a brain scan was made by magnetic resonance imaging. In addition, the 
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total cohort was continuously monitored for incident dementia cases via 
computerized linkage between the study database and computerized medical 
records from general practitioners and the Regional Institute for Outpatient 
Mental Health Care (RIAGG)I3 Dementia diagnosis was made in accordance 
with internationally accepted criteria (NINCDS-ADRDA, NINDS-AIREN, 
DSM-III-R) by a panel that reviewed all existing infonnation.13, 16-18 
Other baseline measurements 
The following baseline variables were used as possible confounders: age, 
gender, diabetes, defIned according to WHO criteria for epidemiological studies 
of diabetes as the use of medication for diabetes or a random or post-load serum 
glucose lcvel greater than II nunoVl19; systolic blood pressure, measured in 
sitting position at the right upper ann with a random-zero sphygmomanometer; 
education, dichotomized in primary education or less and more than prim31Y 
education; smoking, categorized as never, past and current smoking; and body 
mass index (weight (kg)/height (m')). Apolipoprotein E (APOE) genotyping was 
performed on coded DNA samples without knowledge of the diagnosis. The 
polymerase chain reaction product was digested with the restriction enzyme 
Hila!, and fragments were separated by electrophoresis. '0 Homozygotes for the 
APOE*4 allele and heterozygotes were combined and designated as the 
APOE*4 category. During the home interview participants were asked to report 
and show all medication used during the week preceding the interview. 
Subsequently, all drugs were classifIed according to their corresponding 
Anatomical-Therapeutical-Chemical-code (A TC-code ).21 
Statistical Analysis 
We estimated the risk of dementia associated with alcohol consumption in 
categories (no alcohol intake; less than one glass per week; one or more glasses 
per week and less than one per day; I to 3 glasses per day; 4 or more glasses per 
day) with Cox' proportional hazards regression analysis, controlling for age and 
gender. The relative risk was presented with a 95% confIdence interval (95% 
CI). No alcohol intake was used as reference category. To examine whether 
gender or age modifIed the relation we calculated relative risks for men and 
women separately and in strata of age (55-74, 75 years and older). Age and 
gender were evaluated for potential statistical interaction with alcohol by adding 
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scparate terms to the regression models (age (continuously) x alcohol intake 
categOlY; gcnder x alcohol intake categOlY). Sincc stratified analysis on APOE*4 
suggested a stronger effect of alcohol within the strahUn of APOE*4 allele 
carriers, we investigated possible biologic interaction. To investigate the 
combined effect of APOE and alcohol, the study population was dichotomized 
according to alcohol intake and, to yield maximum statistical power, classified 
into four groups: (1) intake of alcohol and APOE*4 allele abscnt (reference 
group); (2) intake of alcohol and APOE*4 allele present; (3) no alcohol intake 
and APOE*4 allele absent; (4) no alcohol intake and APOE*4 allele present. 
Possible interaction was studied according to the principles as described by 
Rothman.22, 23 Briefly, interaction of factors A and B was considered to be a 
departure from additivity, and present if: (RRA+B+ - RRA+B') - (RRA.B+ - I) > O. 
To check if associations could be contributed to confounding, analyscs were 
repeated with possible confounders added to the models (education, smoking, 
body-mass-index, diabetes, and systolic blood pressure). All analyses were 
repeated with dementia subtypes (Alzheimer's disease, vascular dementia) as the 
outcome. 
The risk of dcmentia and dementia subtypes associated with specific types of 
alcoholic beverages was analyzed as follows. For each individual we expressed 
the amount of intake of wine, beer, liquor and fortified wine types as a 
percentage of that individual's total alcohol intake. Next, we added these 
alcohol-type specific variables to the model that already contained amount of 
alcohol intake in categories as described above. The changc in likelihood 
between the model with total amount of alcohol and the model with total amount 
as well as types of alcohol reflects whether the risk of dementia was dependent 
on specific alcoholic beverages rather than on alcohol itself. The risk of 
dementia associated with intake of specific types of alcoholic beverages (beer, 
liquor and fOltified wine typcs) was expressed relative to the risk associated with 
wine drinking. 
To check if the obscrved relation between alcohol intake and risk of dcmentia 
was due to a selection in the referencc group (no alcohol intake) we repeated the 
analyses excluding those who repOlted use of medication in which alcohol intake 
was contraindicated (anxiolytics, antidepressants, and hypnotics), In addition, 
we excluded participants with a histOlY of alcoholism (n ~ 4) and those with 
alcohol consumption Icss than twice a month (n ~ 28), 
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Table 1. Baseline characteristics of participants ofthe Rotterdam Study*' 
Alcohol consumption (no. of drinks) 
No alcohol < I/wk '" I/wk - < l/day I - 3/day '" 4/day 
Number of subjects 1113 1156 151S 1443 165 
Age (years) 69.2 (S.l) 6S.4 (7.S) 67.2 (7.7) 66.9 (7.4) 65.2 (6.4) 
Gender (% women) 75.1 76.5 5S.6 3S.3 13.3 
Blood pressure (mm Hg) 
Systolic 140.0 (22.S) 139.6 (21.9) 137.4 (22.2) 137.4 (21.2) 142.4 (20.S) 
Diastolic 73.0 (11.2) 73.S (11.0) 73.4 (11.2) 73.9 (11.2) 77.4 (10.7) 
Smoking (%) 
Never smoked 47.1 4S.1 33.S 14.S 6.1 
Smoked in the past 33.2 34.9 44.9 55.0 41.2 
Current smoker 19.7 17.0 21.3 30.2 52.7 
Body mass index 26.6 (4.2) 26.6 (3.9) 26.6 (3.5) 26.0 (3.2) 26.1 (3.6) 
Diabetes 14.5 7.9 6.4 9.6 14.9 
Primary education or less 45.9 37.S 30.9 27.7 2S.5 
APOE*4 allele 29.5 25.S 27.1 28.7 22.2 
present(%) 
"'Mean (SO) or percentage 
Alcohol {Jnd dementia 
Finally, we repeated the analyses excluding participants who reported a change 
in their pattern of alcohol consumption in the past five years, as past reported 
intake may not accurately reflect current intake in these paliicipants. 
Results 
During 32,341 person-years of follow-up (mean follow-up of 6.0 years), 197 
participants developed dementia. Alzheimer's disease was diagnosed in 146 
(74.1 %) patients (134 without and 12 with cerebrovascular disease), vascular 
dementia was diagnosed in 29 (14.7 %) patients and 22 (11.2 %) were diagnosed 
with other types of dementia. 
Table I shows the baseline characteristics of the study population according 
to categories of alcohol consumption. Mean alcohol consumption was 0.87 
glasses per day (SD 1.27) and higher for men (1.3 7, SD 1.57) than for women 
(0.51, SD 0.84). As alcohol intake increased, the percentage of never smokers 
decreased sharply. 
Table 2. Distribution ofa1cohol intake in the Rotterdam Study, expressed as proportion (%) of the population 
taking a specific Iype of alcohol and average intake (SD) in those taking that specific type of alcohol. 
Total 
Ivfen 
Women 
% 
21.0 
44.3 
4.8 
Beer 
drinks/day 
0.73 (1.05) 
0.79 (1.10) 
0.32 (0.44) 
Wine 
% drinks/day 
37.0 0.38 (0.57) 
29.6 0.46 (0.67) 
42.1 0.33 (0.51) 
Liquor Fortified wine types 
% drinkslday % drinks/day 
35.0 1.39 (1.49) 32.3 0.51 (0.68) 
60.5 1.56 (1.57) 17.9 0.59 (0.69) 
17.2 0.97 (1.17) 42.4 0.48 (0.68) 
Table 2 shows the distribution of consumption of alcoholic beverages in the 
study population. The mean intake of beer and liquor was higher for men than 
for women and the mean intake of fortified wine types (e.g. sherry, port) was 
higher for women. Men and women drank equal amounts of wine. 
The overall effect of alcohol consumption on the risk of dementia is shown in 
Table 3. Compared to no alcohol consumption, light-to-moderate drinking (l to 
3/day) was associated with a significantly lower risk of dementia (relative risk 
0.58, 95 % CI: 0.38-0.90). The lower risk was most prominent among men, 
although the statistical interaction between gender and alcohol consumption was 
not significant (p ~ 0.49). None of the women drinking four or more drinks per 
day had dementia at follow-up, thus we were unable to estimate relative risks. 
The effect of alcohol was mainly present for vascular dementia (Table 3). 
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Table 3. Relative risk of subtypes of dementia according to alcohol consumption 
RR dementia (95% ell 
(n ~ number of cases) No alcohol < I/wk ~ I/wk - < IIday I - 3/day ~ 4/day 
All dementia Total 1.0 0.82 (0.56-1.22) 0.75 (0.51-LlI) 0.58 (0.38-0.90) 1.00 (0.39-2.59) 
(n~ 197) Men (reference) 0.60 (0.27-1.34) 0.53 (0.28-1.00) 0.40 (0.21-0.74) 0.88 (0.32-2.44) 
Women 0.91 (0.58-1.44) 0.91 (0.55-1.49) 0.85 (0.47-1.57) 
Alzheimer's Total 1.0 0.91 (0.58-1.44) 0.91 (0.58-1.44) 0.72 (0.43-1.20) Ll7 (0.35-3.55) 
disease Men (reference) 0.40 (0.11-1.50) 0.81 (0.35-1.86) 0.52 (0.22-1.20) Ll6 (0.30-4.47) 
(n ~ 146) Women 1.05 (0.64-1.72) 0.92 (0.53-1.62) 0.96 (0.49-1.85) 
Vascular Total 1.0 0.80 (0.30-2.13) 0.37 (0.12-Ll2) 0.29 (0.09-0.93) 1.58 (0.31-8.04) 
Dementia Men (reference) 1.22 (0.30-5.01) 0.31 (0.07-1.41) 0.26 (0.06-1.09) 1.65 (0.29-9.48) 
(n ~ 29) Women 0.50 (0.12-2.0 I) 0.44 (0.09-2.25) 0.46 (0.05-3.92) 
• Adjustment for age, gender, body-mass-index, systolic blood pressure, diabetes, smoking, and education 
AlcollOl and dementia 
As shown in Table 4a, light-to-moderate alcohol consumption was associated 
with a lower risk of dementia both in absence and presence of the APOE*4 
allele. 
Table 4a. Relative risk of dementia associated with alcohol intake slmtified by absence or presence of tile 
APOE*4 allele*. 
APOE*4 absent APOE*4 absent APOE*4 present APOE*4 present 
cases (total) (11 ~ 3743)' cases (total) (11 ~ 1426) 
No alcohol 29 (757) 1.0 (reference) 33 (317) 1.0 (reference) 
< 1/\vk 25 (816) 1.03 (0.60·1. 78) 19 (283) 0.71 (0.40·1.25) 
;::: l/wk - < l/day 29 (1,060) 1.07 (0.62-1.85) 17 (394) 0.46 (0.25-0.84) 
1 - 3/day 16 (987) 0.53 (0.27-1.03) 20 (397) 0.51 (0.28-0.93) 
;::: 4/day 1(123) 0.50 (0.07-3.78) 4 (35) 1.33 (0.45-3.99) 
*Values are relative risks (95% CI), adjusted for age, gender, body-mass-index, systolic blood pressure, 
diabetes, smoking, and education 
tOf226 persons (4 dementia cases) APOB status was not detcnllined 
However, the association with alcohol intake was ah'eady present for lower 
amounts of alcohol intake in carriers of the APOE*4 allele. The interaction 
effect was (4.00 - 1.18) - (2.43 - I) ~ 1.39 (95% CI -0.87 to 3.67)(Table 4b). 
This means that in our sample and when compared to non-APOE*4 carriers who 
did use alcohol, persons who both carried an APOE*4 allele and did not drink 
had a 140% higher risk of becoming demented than one would estimate from the 
separate effects of carrying an APOE*4 allele and alcohol abstinence. 
Table 4b. Relative risk of dementia associated with both alcohol intake and APOE*4. * 
Alcohol intake 
No alcohol intake 
Alcohol intake 
APOE*4 absent 
1.18 (0.75-1.84) 
1.00 (reference) 
APOE*4 present 
4.00 (2.62-6.11) 
2.43 (1.72-3.43) 
*Values are relative risks (95% CI), adjusted for age, gender, body-mass-index, systolic blood pressure, 
diabetes, smoking, and education 
The lower risk of dementia associated with light-to-moderate alcohol drinking 
was more marked in participants younger than 75 years of age than in 
palticipants aged 75 years and older (55-74 years: relative risk 0.43, 95% CI: 
0.23-0.81; ;:> 75 years: relative risk 0.77, 95% CI: 0.42-1.40; p interaction: 0.09). 
However, when we calculated the absolute risk differences between non-
drinking and light -to-moderate drinking in the two age strata, the risk differcnces 
were similar (absolute risk difference 55-74 years: 1.6%;;:> 75 years: 2.2 %). 
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We found no evidence that the risk of dementia or subtypes of dementia 
associated with one type of alcoholic beverage was different from another type 
of alcoholic beverage. A model in which we included specific types of alcoholic 
beverages (wine, beer, liquor and fortified wine types) besides alcohol in 
categories was not significantly better than the model without specific types of 
alcoholic beverages (p ~ 0.40). This is also reflected in Table 5 that shows the 
relative risk of dcmentia associated with either drinking of beer, liquor or 
fortified wine types to wine drinking. 
Table 5. Relative risk of dementia according to specific types of alcoholic beverages (relative risk of drinking 
beer, liquor or wine-types compared to wine drinking)*. 
Total 
Men 
Wine Beer 
1.0 (reference) 
LO (reference) 
0.64 (0.25-1.61) 
0.59 (0.17-2.62) 
Liquor 
1.36 (0.76-2.42) 
1.63 (0.61-4.36) 
Fortified wine types 
1.33 (0.77-2.27) 
1.32 (0.39-4.45) 
Women 1.0 (reference) 1.07 (0.24-4.75) 1.26 (0.59-2.72) 1.26 (0.69-2.29) 
*" Adjusted for age, gender, total alcohol intake in categories, body-mass-index, systolic blood pressure, 
diabetes, smoking, and education 
Only 346 (6.4%) pmticipants reported a change in drinking pattern during the 
last five years. A higher percentage of people with changed drinking patte11ls 
reported drinking less (5.4%), as compared to respondents who repOlted 
drinking more (I %). The results essentially did not change with iterative 
exclusion of participants with changed drinking patterns (6.4%), histOlY of 
alcoholism (0.1%), persons who drank less than twice a month (0.5%), or 
exclusion of binge drinkers (6.2%). 
Medication use that contraindicated drinking alcohol (anxiolytics, hypnotics 
and antidepressants) was reported by 691 (12.8%) participants. Again, exclusion 
of these subjects did not alter the results appreciably. 
Discussion 
We observed that persons with light-to-moderate alcohol intake had a lower risk 
of dementia and vascular dementia than persons who never drank alcohol. This 
lower risk was most robust in men and in participants younger than 75 years of 
age. The effect of light-to-moderate alcohol intake was stronger in carriers of the 
APOE*4 allele. Our data did not suggest a differential effect of specific types of 
alcoholic beverages, besides the effect of alcohol itself. 
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Some limitations of this study have to be considered. Alcohol consumption was 
based on a semiquantitative food frequency questionnaire. Although assessment 
of alcohol intake embedded in a food frequency questio1111aire shows high 
reproducibility,24.26 under- or overrepOtting is possible. Several studies report 
that errors are, in general, linearly related to intake.27 Ifunderreporting is indeed 
linearly related to the level of intake, serious bias in estimates of health risk can 
occur, but it will still be possible to rank subjects according to their alcohol 
intake. Because of this underrepOtting, the amounts of alcohol consumption 
associated with certain health risks may in fact be higher than those indicated. 
An impOttant feature of the Rotterdam Study is that alcohol intake was 
assessed in cognitively healthy persons, before the onset of dementia. Therefore, 
it is unlikely that cognitive impairment has influenced alcohol intake at baseline. 
An advantage is that we were able to examine the risk of dementia associated 
with specific types of alcoholic bevcrages (wine, beer, liquor and fortified wine 
types). 
Earlier, the PAQUlD study in Bordeaux, France7 reported that wine seemed 
associated with a lower risk of dementia. However, wine was the only source of 
alcohol repOtted by more than 95 percent of the regular drinkers in the PAQUID 
study. Therefore, tllis study was unable to distinguish between sources of alcohol 
intake. 
Several mechanisms may be responsible for the inverse relation between 
alcohol consumption and dementia. A first possibility is that alcohol might act 
through reduction of cardiovascular risk factors l ·3 either through an inhibitory 
effect of ethanol on platelet aggregation28 or through alteration of the serum 
lipid profile.29 Our finding that the lower risk was mainly observed for vascular 
dementia is in agreement with this hypothesis. A second possibility is that 
alcohol may have a direct effect on cognition tln'ough release of acetylcholine in 
the llippocampus. There is substantial evidence that acetylcholine facilitates 
learning and memOty.30 It has been suggested that the effect of alcohol on 
acetylcholine release in the hippocampus is biphasic: in rats, a low concentration 
of alcohol (0.8 g/kg) stimulated acetylcholine release, while higher alcohol 
concentrations (2.4 glkg) were inhibitory.31 Tllis might explain our finding that 
light-to·moderate alcohol intake was associated with a lower risk of dementia, 
while higher intake was associated with an increased risk. 
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We found that not drinking alcohol combined with presence of the APOE*4 
allele seemed to be associated with a higher risk of dementia than could be 
expected from the separate relative risks associated with not drinking alcohol or 
presence of the APOE*4 allele. Evidence for a mediating effect of APOE in the 
relation between alcohol and cognitive function has been suggested in one 
study,32 but was not confirmed in another. 33 Oxidation of APOE permits binding 
of APOE to 13-amyloid, which is assumed to increase plaque fOl1nation among 
carriers of the APOE*4 allele.34 The antioxidative effect of alcohol may 
suppress this binding.35 Alternatively, since APOE*4 is associated with lower 
levels of HDL cholesterol and higher levels of LDL cholesterol, light-to-
moderate alcohol consumption may protect against dementia by improving the 
lipid profile of APOE*4 caniers.36 
The detailed food frequency questionnaire enabled us to examine various 
amounts and different sources of alcohol intake, rather than just examining the 
risk associated with absence or presence of alcohol intake.37 Our observation 
that there is no difference in risk associated with different types of alcoholic 
beverages is consistent with recent findings of the Canadian Study of Health and 
Aging3S and with findings from several studies on coronary healt disease. 1,39,40 
In conclusion, we found that light-to-moderate alcohol intake was associated 
with a lower risk of dementia and vascular dementia irrespective of the source of 
alcohol intake. Light-to moderate alcohol consumption diminished the effect of 
APOE*4 on the risk of dementia. These findings are compatible with the view 
that light-to-moderate alcohol consumption may lower the risk of dementia in an 
elderly population. 
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5 
PROGNOSIS OF 
DEMENTIA 

5.1 
Prognosis of Alzheimer's disease. 
The Rotterdam Study 
Abstract 
The aim of this stU(!)' was to construct a prognostic mode! to predict the 
progression of Alzheil1ler~\' disease. Prevalent and incident cases with 
Alzheimer's disease came from the Rotterdam Study, a population-based 
prospective cohort study of persons aged 55 years and older, including those 
living in institutions. Rate of cognitive decline, as measured by the ,"lini-Mental 
State Examination (A!JvISE score), was predicted by a random effects model. 
Risk of institutionalization and death were estimated with polynomial logistic 
regression analysis. 
At baseline, 306 subjects were diagnosed with prevalent Alzheimer's disease and 
had complete data on living conditions and cognitive jimctiol/. After a mean 
follow-up of 2.1 years, 95 subjects with incident Alzheimer's disease had been 
diagnosed Prevalent patients showed a slower decline in cognitivefilllction than 
incident patients (p ~ 0.004). For prevalent and incident Alzheimer's disease 
patients high age and low cognitive peljol'l1Iance were the strongest predictors 
for institutionalization and death. 
These prognostic risk jill1ctions can provide il!formation on the decline of 
Alzheimer patients and might be used to better evaluate the effect of treatments 
for Alzheimer's disease. 
Introduction 
Alzheimer's disease (AD), the most frequent subtype of dementia,l is an 
important cause of disability in the elderly. Several studies have shown an 
exponential increase in the incidence rate of AD with age2, 3 and because of the 
aging of our western population we may expect a dramatic rise in the number of 
patients with AD in the years to come. Since there is as yet no cure for AD, the 
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majority of AD patients will need long term care, which imposes a major burden 
on the health care system. In the Netherlands, about one tenth of the yearly 
health care budget is spent on nursing homes, and in 40% of the nursing home 
patients, dementia is the main diagnosis.4 
Death and admissions to cln'onic care facilities represent two major outcome 
events in the natural course of AD with a direct bearing on the costs. 5• 6 Current 
knowledge on the prognosis of dementia and AD is limited. Most studies have 
focused on relatively young-old adults (65+ years) and repOlted on hospital or 
nursing home populations,?-II Although numerous population based prognostic 
studies on prevalent Alzheimer patients have been done,12-16 studies on incident 
Alzheimer patients from population-based cohorts are limited. 17, 18 
The aim of this study is to develop a risk function to predict the prognosis of 
Alzheimer patients in different disease stages, based on cognitive decline, 
institutionalization and death. Because analyses based on prevalent cases include 
a mixture of new and long existing cases, this may lead to an ovcrrepresentation 
of long existing cases and thus to biased estimates of survival. Therefore, we 
studied disease progression separately for incident and prevalent Alzheimer 
patients. 
Materials and Methods 
Study design and population 
Patients with Alzheimer's disease came from the Rotterdam Study, a population-
based prospective cohort study among persons aged 55 years and older, 
including those living in institutions. 19 Baseline examinations, including a home 
interview and an extensive physical examination, took place between 1990 and 
1993. Of the 7,983 subjects who participated (response 78%), 7,528 (94%) 
underwent extensive screening for dementia. At baseline, 482 subjects were 
diagnosed with dementia, of whom 353 had Alzheimer's disease3 , 20 This 
resulted in a cohort of 7,046 subjects at risk for dementia. In 1993 and 1994 
follow-up examinations took place. In addition, the cohort was continuously 
monitored by means of computerized linkage of the study database with medical 
records from general practitioncrs and the Regional Institute of Outpatient 
Mental Health Care (RIAGG). 
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After a mean duration of follow-up of 2.1 years, 162 incident cases of dementia 
had been identified, and 116 of them were diagnosed with Alzheimer's disease.3 
Information on living conditions, Mini Mental State Examination (MMSE) at 
time of study diagnosis and vital status at follow-up was available for 306 
patients (86.7 percent) with prevalent AD and for 95 patients (81.9 percent) with 
incident AD. Both prevalent and incident patients were followed until the end of 
the study period (censoring date was April I, 1998). 
Dementia diagnosis 
Similar screening and diagnostic procedures for dementia were used at baseline 
and follow-up2o. First, a brief test of cognition (MMSE and Geriatric Mental 
Schedule organic A (GMS)) was administered. Screen-positives (MMSE < 26 or 
GMS >0) underwent flllther neuropsychological testing by one of the study 
physicians with the CAMDEX diagnostic interview, which included an 
informant interview. Subjects who were suspected of dementia were examined 
by a neurologist, tested by a neuropsychologist and, if possible, underwent a 
brain MRI. Dementia diagnosis was made according to DSM-III-R criteria by a 
panel that reviewed all existing information. A subdiagnosis of AD was made 
according to the NINCDS-ADRDA criteria.21 
At baseline, 18% of the subjects screened in person was screen positive. Of 
those, 92% underwent the CAMDEX diagnostic interview. Many subjects with 
dementia were resident in_six homes for elderly people, which were included in 
the study. These homes had psychogeriatric depaltments. Often, subjects were 
already known to be demented. Of these subjects and 8% of the screen positive 
subjects who refused the CAMDEX interview or could not be examined, 
diagnostic information was obtained from the general practitioner, physicians in 
the homes, neurologists or the RlAGG. 
At follow-up examination, 79% of the total cohort at risk to develop 
dementia was screened in person for dementia. Of those, 10% were screen 
positive on the cognitive screening test. Of those who were not examined at 
follow-up and of whom information on dementia was solely obtained through 
general practitioners and the RlAGG, 476 had died and 999 refused the 
screening test. 
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Cognitive .{illlction 
To assess cognitive decline we used the Dutch version of the 30-point MMSE, 
which was used to screen for dementia.22 The MMSE includes questions on 
orientation to time and place, registration, attention and calculation, recall, 
language and visual construction. Although this screening test was originally 
created for a clinical setting, it is extensively used in epidemiological studies, 
and has proven to be a reliable and valid indicator of cognitive impainnent2, 23 
and cognitive decline. 12, 24, 25 
Of the 306 prevalent Alzheimer patients who had a MMSE measurement at 
baseline, 35% died between baseline and re-examination. At follow-up (on 
average 2 years later), 82 or the 199 patients who were still alive had a second 
reliable MMSE assessment. On 88 of the 95 incident Alzheimer patients blood 
was available for APOE testing and those were invited for additional 
standardized follow-up examinations by a neurologist, at intervals of 
approximately 15 months. Of the 73 patients who were still alive 15 months 
after the fll'St examination, 61 agreed to participate and of the 42 who were alive 
at time of the third examination, 40 patients pat1icipated. 
Activities of daily living 
At the baseline home interview we administered the Katz-index26 (activities of 
daily living) and the Lawton scale27 (instlUmental activities of daily living). 
Because in our questionnaire the question about continence was lacking we 
made a five-point scale on the ADL score. The IADL score was categorized in 
three groups: 0-6, 6-12, >12. Missing data on one or two items of the ADL or 
IADL scale were imputed according to dementia severity class (CDR-score).28 
When subjects had more than two missing items, the total score was considered 
missing. 
Insti tlltionalization 
Living conditions (living independently, in a home for the elderly or in a nursing 
home) were obtained from the municipality for each pm1icipant at the baseline 
and follow-up examination, at the time of death, and at the censoring date (April 
I, 1998). Home for the elderly is defined as medium care (breakfast and diner 
are supplied, assistance with dressing). Nursing home is defined as full care. The 
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midpoint between two dates was used as the date of transition from one 
condition to the other. 
Mortality 
Vital status of the participants was obtained from the municipality and general 
practitioners on a biweekly basis. The end of the follow-up period was set at 
April 1, 1998. 
Other }.1easllrements 
As possible predictor variables we considered the following: age, gender, level 
of education (completed primalY education, lower vocational or general 
education, and intennediate or higher vocational or general education, college or 
university) (UNESCO), and caregiver availability (living alone or living with a 
partner or relative). Apolipoprotein E (APOE) genotyping was performed on 
coded DNA samples without knowledge of the diagnosis. The polymerase chain 
reaction product was digested with the restriction enzyme Hha!, and fragments 
were separated by electrophoresis.29 
Statistical analysis 
To compare baseline characteristics of prevalent and incident Alzheimer cases 
we used a t-test (age), nonparametric tests (Kruskall-Wallis) for continuous 
variables (MMSE), and chi-square tests for categorical variables. 
We fll'st developed a function to estimate an individual's rate of cognitive 
decline based on celtain initial characteristics with a random effects model (SAS 
6.12, PROC MIXED). We assumed a linear rate of decline. We used all baseline 
and follow-up MMSE-measurements as outcome variables and age, gender, 
education, follow-up time and an interaction term of time with all of the other 
variables as covariates. The intercept and time variables were specified as 
random effects. Addition of baseline ADL, IADL or caregiver availability did 
not statistically improve the model at the a ~ 0.05 level. APOE genotype did 
improve the prediction function and was therefore included in the model. 
Separate models were made for prevalent and incident patients. We also made a 
combined prediction function for prevalent and incident cases to test whether 
they declined at a statistically significant different ratc. 
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Second, we developed a set of functions to estimate an individual's absolute risk 
of institutionalization and death based on certain characteristics. Several 
transitions were considered possible: from living independently to a home for 
the elderly, from a home for the elderly to a nursing homc, or from living 
independently to a nursing home. Furthcl1nore subjects were always at risk of 
dying. The follow-up time of each subject was divided in intervals of six 
months. We made separate rccords for every subject at each interval, containing 
the living situation at start and end of the interval, and a number of covariables. 
Out of these records we composed tlu'ee datasets, based on the living situation at 
the begilUling of the interval (subjects living independently, subjects living in a 
home for the elderly and subjects living in a nlll'sing home). Polynomial logistic 
regression analysis (SAS 6.12, PROC CATMOD), with age, gendcr and 
predicted MMSE score at start of the interval included as covariatcs, provided 
conditional odds ratios of possible transitions for each of the three living 
conditions. Out of these conditional odds ratios, absolute risks of 
institutionalization or death could be calculated given a certain age, gender, and 
MMSE score. To compare the risk of institutionalization and death between 
incident and prevalent patients we made a combincd function adding interaction 
terms of all the covariates with an indicator for prevalent or incident patient. 
Results 
Baseline characteristics of the prevalent and incident Alzheimer cases are given 
in Table I. Prevalent and incidcnt cases were similar with respect to age and 
gender. At time of first examination after diagnosis more prevalent cases lived in 
a home for the eldcrly. None of the dementia cases lived in a nursing home at 
baseline. As expected, prevalent patients were in a more severe stage of the 
disease and performed worse on the MMSE. They were also less educatcd. The 
mean duration of disease in prevalent Alzheimer patients was 3.1 years (SD 2.6). 
After a mean follow-up of 2.2 yrs (SD 1.25) 74.2 percent (n = 227) of the 
prevalent cases had died. At time of death or at the end of the study period 15.7 
percent (n = 48) lived at home, 60.8 percent (n = 186) lived in a home for the 
elderly and 23.5 percent (n = 72) lived in a nursing home. After a mean follow-
up of2.8 yrs (SD 1.28),53.7 percent (51) of the incident cases had died. At time 
of death or at the end of the study period 25.3 percent (n = 24) of the incident 
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cases stiIllived at home, 44.2 percent (n = 42) in a home for the elderly and 30.5 
percent (n = 29) in a nursing home. 
Table 1, Characteristics ofshldy population at time of fIrst examination after disease onset: Rotterdam Study 
(1990·1998). 
Prevalent Alzheimer's disease Incident Alzheimer's disease 
N~306 N~95 
~'fean age (years)(SD) 84.9 (6.5) 84.3 (7.2) 
Gender (% women) 77.1% (236) 80.0% (76) 
Living in home for elderly at baseline (%) 69.0% (211) 45.3% (43) 
Severity of disease (CDR) % (n) 
1Hnimal 17.3% (53) 24.2% (23) 
Mild 39.9% (122) 60.0% (57) 
Moderate 31.4% (96) 14.7% (14) 
Severe 11.4 %(35) l.l% (1) 
Education (%) (n) 
Low 77.1(168) 69.1 (56) 
Intermediate 14.7 (32) Il.l (9) 
High 8.3 (18) 19.8 (16) 
~"ledian (range) baseline MtvlSE 17.2 (0·28) 19.7 (11·27) 
APOE*'4 (%) (n) 87 (28) 30 (32) 
APOE*2 (%) (n) 32 (10) 8 (8) 
APOE*3 (%) (n) 134 (44)* 50 (53) 
*53 (I 7%) of prey alent and 7 (7%) of incident patients had no information on APOE status 
APOE*4: apolipoprotein-E £2/£4, £3/£4, or £4/£4 genotype 
APOE*2: apoJipoprotein-E £2/£2, £2/e3 genotype 
APOE"'3: apolipoprotein-E £3/£3 genotype 
The variables that were finally included in the prediction function for MMSE 
were gender, age, education, ApoE genotype, follow-up time in years and 
interaction terms of time with all those variables (for coefficients see table 2). As 
an example, we used these coefficients to calculate the change in the predicted 
MMSE-score over time for a prevalent case and an incident case, separately for 
a highly educated male and female person aged 80 years (Figure 1). Prevalent 
cases started at approximately the same MMSE level as incident cases but 
showed less decline in the MMSE score than incident cases (p = 0.004). 
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Table 2. Estimated coefficients to predict the M1\'fSE-score at a given point in time for Alzheimer patients: 
Rotterdam Study (1990-1998). 
Prevalent AD (n = 306) 
coeftlcient 
Intercept 32.92 
Male -0.79 
Female reference 
Age (years) -0.15 
Primary education -1.05 
Intermediate education -0.42 
High education reference 
APOE*4 -1.27 
APOE*2 0.55 
APOE"'3 reference 
Time (yrs) -4.65 
T*male ·0.11 
T*female reference 
T*age 0.03 
T*primury education 0.55 
T*intermediate education 0.92 
T*high education reference 
T*APOE*4 0.59 
T*APOE*2 0.02 
T*APOE*3 reference 
APOE*4: apolipoprotein-E E2/£4, £3/£4, or £4/£4 genotype 
APOE*2: apolipoprotcin-E f2/E2, £2/E3 genotype 
APCE*3: apolipoprotein-E 123/£3 genotype 
T = time in years, T*coyariate = interaction of time with coyariate 
Incident AD (n = 95) 
coefficient 
23.71 
1.10 
reference 
·0.05 
·0.20 
0.20 
reference 
0.57 
·0.47 
reference 
0.45 
-0.11 
reference 
-0.04 
0.36 
1.33 
reference 
-0.28 
-1.61 
reference 
In table 3 and 4 the coefficients from the polynomial logistic regression analyses 
to estimate the transition probabilities for living situation are given. Appendix I 
dcmonstrates how to usc the coefficients. For AD cases living at home, age was 
the strongest predictor for moving to a home for the elderly. Women with 
prevalent AD were at higher risk of entering a home for the elderly after one 
year compared to men with prevalent AD. Low MMSE was a major predictor 
for institutionalization and death for prevalent as well as for incident AD 
patients. 
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Table 3. Coeflicients from a polynomial logistic regression model to estimate transition probabilities for a 
prevalent Alzheimer patient: Rotterdam Study (1990-1998). 
Living situation at 1=0 
At home 
Home for elderly 
Nursing home 
Intercept 
Time 
Age 
Female 
lvlMSE 
Intercept 
Time 
Age 
Female 
MMSE 
Intercept 
Time 
Age 
Female 
MMSE 
Home for elderly 
estimate p-value 
-19.48 <0.001 
-0.07 0.75 
0.19 <0.001 
2.25 0.05 
-0.14 0.10 
Living situation at t = 1 
Nursing home 
estimate p-value 
-2.98 0.19 
0.30 0.04 
-0.01 0.86 
-0.05 0.89 
-0.001 0.99 
-0.80 0.80 
0.29 0.02 
-0.03 0.46 
0.54 0.38 
-0.09 0.007 
Death 
estimate p-value 
-3.87 0.14 
-0.07 0.70 
0.05 0.08 
-0.76 0.09 
-0.18 <0.001 
-5.42 0.002 
0.08 0.26 
0.06 0.003 
-0.61 0.007 
-0.08 <0.001 
-6.31 0.05 
-0.20 0.35 
0.07 0.05 
-0.19 0.75 
-0.06 0.14 
Table 4. Coefi1ciellts from a polynomiallogistie regression model to estimate transition probabilities for an 
incident Alzheimer patient: Rotterdam Study (1990-1998). 
LiYing situation at t = 0 
AI home Intercept 
Home for elderly 
Nursing home 
Time 
Age 
Female 
MMSE 
Intercept 
Time 
Age 
Female 
MMSE 
Intercept 
Time 
Age 
Female 
MMSE 
Home for elderly 
estimate p-value 
-19.64 0.006 
-0.35 0.38 
0.18 0.01 
-0.49 0.59 
0.06 0.63 
Liying situation at t = 1 
Nursing home 
estimate p-value 
2.57 0.44 
-0.57 0.02 
-0.01 0.71 
0.10 0.85 
-0.21 <0.001 
13.93 0.09 
-1.25 0.08 
-0.21 0.03 
6.66 <0.001 
-0.30 0.06 
t - 0: time of study diagnosis; t - 1: living sih.13tion after one year after study diagnosis 
Death 
estimate p-yalue 
-6.42 0.26 
0.15 0.62 
0.05 0.46 
0.02 0.98 
-0.09 0.23 
-8.90 0.04 
-0.64 0.009 
0.11 0.02 
-1.00 0.13 
-0.10 0.17 
-4.96 0.39 
-0.45 0.19 
0.04 0.56 
0.02 0.98 
0.11 0.04 
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Female, age 80 Male, age 80 
25 25 1 
~ 11 20[:" , ~ 15 - ' ~' _____ .. ::;: 10~ 5 ' .• O~, i' i 
o 2 3 4 5 o 2 3 4 5 
Time (years) Time (years) 
--+-- prevalent incident --+- prevalent incident 
Figure 1. Change in I\H..1SE-score oyer time based on patient characteristics. 
Figure 2 shows the transition probabilities for a female patient, with an MMSE-
score of 15, living at home at baseline. Probabilities are shown for age 70, 80 
and 90. The probability to enter a home for the elderly increased with age. This 
pattern is observed in both prevalent and incident Alzheimer cases, although less 
clearly among incident cases. 
Prevalent patient 
100% 
80% 
60% 
70 
III staying at home 
o nursing home 
80 90 years 
Iii home for elderly 
Odeath 
Incident patient 
100% I_i i 80% 
60% 
70 80 90 years 
III slaying al home IBholllC for elderly 
o nursing home Odeath 
Figure 2. Transition probabilities after one year for a female patient, l\{r-.1SE = IS, living at home at baseline, 
for different ages. 
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As an example figure 3 shows the transition probabilities for a female, aged 80 
with an MMSE-score of 15 living at home (a), living in a home for elderly (b) 
and living in a nursing home (c). From the combined prediction function we 
could estimate that prevalent cases had a slightly higher probability to die than 
incident cases, except when they already were living in a nursing home. 
Living at home 
100% 
80% 
60% 
prevalent incident 
.staying at home IliJhome for elderly 
Onursing hom£> Ddeath 
Living in home tor elderly 
100% 
SO% 
60% 
mhome for elderly o nursing home Odeath 
Living in nursing home 
prevalent incident 
Onufsing horne Ddcath 
Figure 3. Transition probabilities after 
one year for a female patient age 80, 
MtvlSE = IS, living at home, in a home 
for the elderly or in a nursing home, 
Incident cases living in a nursing home had 
a 35 percent chance of mortality after one 
year, compared to 12 percent among 
prevalent cases. These differences, 
however, were non-significant (p ~ 0.84). 
Incident cases also seemed to move more 
quickly from a home for the elderly to a 
nursing home compared to prevalent cases 
(p ~ 0.09). For male subjects these results 
were more or less the same, except that the 
probability to remain in a home for the 
elderly was higher among incident male 
compared to incident female cases. 
Discussion 
In this large population-based study we 
developed prognostic risk functions to 
predict cognitive decline and a function to 
predict risk of instihltionalization and death 
based on certain individual baseline 
characteristics. Since the prevalent and 
incident cases were analyzed separately, the 
effect of different stages of disease could 
be examined. We observed a steeper 
decline in cognitive function for incident 
compared to prevalent AD cases. 
Moreover, incident dementia cases that 
lived in a home for the elderly at baseline 
were more likely to move to a nursinghome 
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during follow-up than prevalent cases. 
Major advantages of the Rotterdam Study to investigate progression of 
disease include the longitudinal and population-based design and the complete 
follow-up with respect to institutionalization and mortality. 
A limitation of this study is that the prediction model for cognitive function is 
based on a maximum of three measurements of the MMSE. However, with the 
random effects model we could include all cases, not just those who survived 
long enough to have two or three measurements. Another limitation is that we 
lacked the power to examine the effect of comorbidity (stroke, myocardial 
infarction) on institutionalization and death. 
We assumed a linear decline in cognitive function. A trilinear model of 
decline has also been proposed, in which rapid change occurs in the midrange of 
disease severity with relative plateaus early and late in the disease.3o This 
trilinear model would explain why we find a more rapid decline for the incident 
Alzheimer patients compared to the prevalent patients. Cases in the more severe 
stages of disease could have reached the plateau phase late in the disease. 
Katzman et aPI found that only the most severely demented showed a slower 
rate of subsequent decline and attributed the finding to a floor effect. 
Furthenllore, the non-linear trend appears to be small and linear models seem to 
prove the best fit to longitudinal cognitive data in Alzheimer's disease.32 
Therefore, we used the linear model. 
Several studies have repOlted severity of dementia (MMSE score, ADL, 
CDR) at study entry to be a major predictor of time to admission to a nursing 
homeJ-lo In Alzheimer's disease, several factors have been related to shOlter 
survival. These include functional disability,?, 33, 34 male genderll , 34, 35 and 
increasing age. ll, 34, 35 Aguero-Torres et al. 12 found in a longitudinal population-
based study that shorter survival was related to male gender, advanced age, low 
education level and functional disability at baseline. In our study we found that 
male gender, advanced age and a low MMSE score at the beginning of an 
interval were associated with shorter survival. The better prognosis in women 
can probably be partly explained by the fact that healthy women have a higher 
life expectancy at any age. I I The survival advantage of women with AD relative 
to men may also occur as a result of fewer cOl11orbid clinical conditions 
associated with the diagnosis of dementia.37 ADL and IADL did not enter the 
model for predicting MMSE. It is possible that this was partly due to the global 
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scales that we used, however, it is also possible that ADL and IADL are less 
important in predicting cognitive decline in demented subjects than in predicting 
dementiaJ, 38 We were not able to evaluate the role of ADL, IADL and caregiver 
availability in predicting institutionalization and death because we lacked 
detailed information on these items at the beginning of each 6-month interval. 
In this study we developed a function to predict an individuals decline in 
MMSE score over time and to predict the risk of institutionalization and death. 
We showed a major difference in predicted prognosis between prevalent and 
incident Alzheimer cases. There probably was an overrepresentation of slowly 
progressive dementia and an underrepresentation of rapidly progressive 
dementia among the prevalent dementia cases, since the rate of cognitive decline 
was lower among prevalent than among incident cases. This might be the result 
of a higher mOltality among velY rapidly progressive dementia cases. Patients 
derived from a cross-sectional study tend to be less rapidly progressive with 
respect to cognitive decline, institutionalization, and mortality compared to 
patients derived from a longihldinal shldy. 12, 39 
Prognostic models from epidemiological shldies can provide information on 
the decline of a group of Alzheimer patients or can be used to get a prediction 
about an individual's prognosis. The coefficients derived from these models can 
be used to construct a simulation model of the disease process. Such simulation 
models allow the estimation of the possible impact of a treatment, for example 
with relation to health costs. Finally, prediction of the risk of institutionalization 
and death of Alzheimer's disease may be useful for health care planning on a 
larger scale.4o 
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Appendix 1: 
Example: What are the probabilities for an SO year old woman with Alzheimer's 
disease who is living at home and has a MMSE score of IS, that one year later 
a. she will live in a home for the elderly 
b. she will live in a nursing home 
e. she will have died 
d. she will still live at home 
a. Logodds to move fi'om home to home for the elderly: 
intercept+T*1+age*SO+female* I +MMSE*15 = -3.S5 
Odds to move from home to home for the elderly: 
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EXP(-3.S5) = 0.021 
Probability to move from home to home for the elderly: 
1/(1+ 0.021) 
Absolute probability to move from home to home for the elderly: 19.4 % 
(Formula I) 
Prognosis of dementia 
b. Logodds to move from home to a nursing home: -3.13 
Odds to move from home to a nursing home: 
EXP(-3.13) ~ 0.044 
Probability to move from home to a nursing home: 1/(1+0.044) 
Absolute probability to move from home to a nursing home: 
4.0 % (Formula 2) 
c. Logodds to die when living at home: -3.27 
Odds to die when living at home: EXP(-3.27) ~ 0.038 
Probability to die when living at home: 1/(\+0.038) 
Absolute probability to die when living at home: 
3.4 % (Formula 3) 
d. Absolute probability to stay at home: 
1- (Pddedy+PUll",+Pde"h) ~ 90.7 % 
Formula 1: P ddedl' *(l-P Ull")*( I-P de"h)/( I-(P eldedl' *p Ull"')-(P ddedl' *p de"h)-
(P nursc *p dcatb)+ (2 *p cldcrly*P nurs *p deatb)) 
Formula 2: PUll'" *(I-P dd"ll')*( I-P 'e"h)/( I-(P dd,d,.*P Ull"')-(P eldodl' *p 'e"h)-
(P nurse *p deatb)+ (2*Phome *p elderly *Pnurs)) 
Formula 3: P d,,,h *(l-P mu,,)*( 1-Pdd,dy)/(l-(Pdd,dy *p nll",)-(Pdd,dy *p '''Ih)-
(Pllurse *p death)+ (2 *Phome *P elderly*P nuTS)) 
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General discussion 
The aim of the research described in this thesis was to fmther elucidate the role 
of vascular pathology in dementia and Alzheimer's disease and to identifY 
possible underlying mechanisms. 
All chapters in this thesis are based on studies perf0l111ed within thc 
Rotterdam Shldy, a large population-based prospective COhOit study that is 
ongoing since 1990 and includes 7,983 participants of 55 years and older. The 
COhOit at risk for dementia consisted of 7,046 persons who havc been followed 
from baseline up to December 31, 1999. The cohort was re-examined twicc 
(1993-1994; 1997-1999). In addition, the cohort is continuously monitored 
through linkage of the Rotterdam Study database with medical records from 
general practitioners and the Regional Institute for Outpaticnt Mental Health 
Care (RIAGG). During 40,441 person-years of follow-up, we identified 395 ncw 
cascs of dementia. 
In the following we will rcvicw our main findings and discuss them in the 
light of other shldies and current insights in the relation between vascular factors 
and Alzheimer's disease. Subsequently we will discuss the clinical relevance of 
our fmdings. We will end with some recommendations for future research. 
Main Findings 
Until December 31, 1999 we identified 395 patients with incident dementia 
within the Rotterdam Shldy cohort, for an overall incidence rate of dementia of 
9.8 per 1,000 person-years in those of 55 years of age or over. Alzheimer's 
disease was most frequently diagnosed (74%), followed by vascular dementia 
(14%). The overall incidence rate of dementia was velY similar for men and 
women, as were age-specific incidence rates up to the age of 90 years. Women 
werc more likely to develop Alzheimer's disease, whereas men were more often 
diagnosed with vascular demcntia. TIlls difference can possibly bc explained by 
a higher stroke incidcnce in men or a misclassification of vascular dementia into 
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Alzheimer's disease in women, since cerebrovascular pathology may less often 
be symptomatic in women. l After 90 years of age the incidence rate of dementia 
declined in men but not in women, probably due to more selective survival in 
men. 
We took two different approaches to address the issue of possible vascular 
involvement in the aetiology of dementia and Alzheimer's disease. First, we 
investigated the relation between vascular risk factors and markers of vascular 
disease and the occurrence of dementia, in patiicular Alzheimer's disease. 
Second, we investigated whether cerebrovascular impairment was associated 
with Alzheimer's disease. 
Vascular riskfClctors and lIIarkers/or vascular disease 
We investigated blood pressurc, change in blood prcssure, alcohol consumption, 
and markers of atherosclerosis in relation to the risk of dementia, Alzheimer's 
disease and vascular dementia. 
At short-term follow-up (on average 2 years), blood pressure was not 
associated with risk of dementia in persons younger than 85 years of age, 
whereas in older persons increasing levels of blood pressure were associated 
with lower risks of dementia. Also, use of blood pressure lowering medication 
was associated with a lower risk of dementia and vascular dementia. By contrast, 
at longer follow-up (on average 6 years), higher baseline blood pressure levels 
were associated with an increased risk of dementia, in particular for persons 
younger than 75 years. A declinc in blood pressurc was associated with an 
increased risk of Alzheimer's disease and vascular dementia in the years 
thereafter. Our findings fit with results from several other longitudinal studics2• 3 
and suggest that high blood pressure increases the long term risk of dcmentia. It 
remains a question how a decline in blood pressure is related to risk of dementia. 
Some authors suggested that lowering of the blood pressure beyond a critical 
threshold increases the risk of dementia through chronic hypoperfusion, 
especially in elderly persons with longstanding hypertension4 , 5 An alternative, 
but equally possible, explanation is that a decline in blood pressure is a 
consequence of brain lesions associated with dementia, since several areas that 
are involved in central blood pressurc regulation are affected in Alzheimer's 
disease.6,7 In support of this, we found that blood pressure was lower in subjects 
124 
General discllssion 
with manifest dementia at baseline and dee1ined more rapidly in this group than 
in the non-demented during follow-up. The explanations are not mutually 
exe1usive. 
We found that light-to-moderate alcohol intake (1-3 glasses per day) was 
associated with a lower risk of dementia and vascular dementia, irrespective of 
the source of alcohol intake. It has bcen suggested that the association of alcohol 
with dementia is through release of acetylcholine in the hippocampus.8 
However, the fact that associations were strongest for vascular dcmentia makes 
it more likely that the effect is through reduction of cardiovascular risk factors,9-
II either through an inhibitOlY effect of ethanol on platelet aggregationl2 or 
through alteration of the serum lipid profile. 13 The beneficial effect of alcohol 
intake was stronger in carriers than in non-carriers of an apolipoprotein £4 allele. 
Since the £4 allele is associated with lower levels of HDL cholesterol and higher 
levels of LDL cholesterol, light-to-moderate alcohol consumption may protect 
against dementia by improving the lipid profile of apolipoprotein £4 allele 
carriers.14 Alternatively, alcohol may suppress oxidation of apolipoprotein-Els 
that permits binding to ll-amyloid, which is assumed to increase plaque 
formation among carriers of the apolipoprotein £4 allele. 16 
Plaques in the carotid arteries and thickening of the carotid artery vessel wall 
significantly increased the risk of dementia and Alzheimer's disease. The risk of 
dementia increased with the amount of atherose1erosis. The same trend was 
observed for Alzheimer's disease and vascular dementia. Atherosclerosis can be 
related to dementia in several ways. Atherosclerosis may cause hemodynamic 
changes leading to neuronal damage in vulnerable areas of the brain. Also, 
atherose1erosis may impair the blood-brain barrier function as a result of cerebral 
vessel wall damage. 17 Finally, vascular damage associated with athcrose1erosis 
superimposed on alrcady existing Alzheimer pathology may lead to an earlier 
detection of otherwise subclinical Alzheimer's disease. 
Functional cerebrovascular ill/pairll/ellt 
Transcranial Doppler is a non-invasive tool to measure cerebral blood flow 
velocity and cerebrovascular CO, reactivity in cerebral arteries. We obtained 
TCD assessment on 2,107 participants in the second re-examination of the 
Rotterdam Study. Cerebral blood flow velocity was significantly lower in 
persons with dementia, but also in persons with cognitive dee1ine, without 
125 
Chapter 6 
dementia. Reduced blood flow velocities may represent consequences of 
reduced metabolic needs due to neuronal tissue loss.18, 19 Alternatively, a decline 
in cerebral blood flow velocity may be a risk factor for dementia, due to a 
decreased delivelY of oxygen and resulting hypoxia.2o The observation that 
cerebral blood flow velocity was already lower in persons with cognitive 
decline, without dementia, does fit both explanations. Cerebrovascular CO, 
reactivity was lower in persons with cognitive decline and in those with low 
cognitive performance and seemed lower in persons with dementia. 
Atherosclerosis may disturb the integrity and function of the mterial wall and 
thereby affect cerebrovascular CO, reactivity. A low cerebrovascular CO, 
reactivity may also indicate small vcssel pathology.21 Our findings support the 
hypothesis of a role for vascular risk factors and vascular disease in the aetiology 
of cognitive decline and dcmentia. Whether the lower blood flow velocity and 
vasomotor response are a cause or a consequence of dementia can not be judged 
from this cross-sectional study. 
Main hypotheses 
There are at least four mechanisms that may underlie the association between 
vascular factors and dementia (see figure). 
1. AD pathology ~ Alzheimer's disease 
Vascular factors 
• 
Vascular disease, vascular dementia 
2. Vascular factors • Alzheimer's disease 
3. Alzheimer's disease ~ Vascular factors 
4. 
Vascular ~ctors 
AD pathology • Alzheimer's disease 
1. Co-incidence of Alzheimer's disease and vascular dementia (co-morbidity): 
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on existing Alzheimcr pathology may act to unmask otherwise subclinical 
Alzheimer's disease.22 More than one third of Alzheimer cases exhibit 
variable cerebrovascular pathology, even though Alzheimer's disease is 
diagnosed at autopsy.23 And patients with vascular dementia often have 
Alzheimer pathology at autopsy even though there was no clinical picture of 
Alzheimer's disease. The pathology that causes clinical symptoms fn'st, may 
determine whether the dementia syndrome is classified as Alzheimer's 
disease 01' as vascular dementia, whereas the majority of cases are actually 
mixed-type dementias. 
2. Vascular factors cause Alzheimer's disease. Most vascular risk factors 
impair or reduce cerebral perfusion in some way. Impaired perfusion will 
affect the microcirculation and delivelY of energy substrates required for 
optimal brain cell function.4 Disturbances in the glucose-oxygen delivery to 
neurons can lead to abno1111al protein synthesis and eventually to production 
of senile plaques and neurofibrillary tangles. 
3. Alzheimcr's disease causes vascular factors. The relation may be inverse, 
and there is actually some evidence that this is sometimes the case. 
Deposited Il-amyloid has a toxic effect on vascular cndothelium.24 Metabolic 
and ncuronal changes that occur in the course of Alzheimer's disease may 
lead to a disturbed central blood pressure regulation and to autonomic 
dysfunction with orthostatic hypotension and decreased healt rate 
variability,? 25 
4. Biological interaction between vascular factors and Alzheimer pathology. 
Vascular pathology and Alzheimer pathology may enhance each other in 
bringing out a dementia syndrome. Vascular disorders, such as chronic 
hypertension, are associated with increased vascular permeability with 
protein extravasation,17 The impaired blood brain barrier function increases 
the possibility that substances from serum penetrate the blood brain barrier 
and reach the brain, where they may interfere with neuronal function and 
may lead to amyloid accumulation. The distribution of amyloid was found to 
be related to blood vessels, suggesting that its origin may be vascular rather 
than neuronal26 Vascular factors may also accelerate the pathogenesis of 
Alzheimer's disease through ischaemia and resulting formation of free 
radicals.27 
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Which of the four outlined schedules is the correct one? Vascular factors and 
Alzheimer pathology may co-exist and probably they do. However, mechanism 
I can not explain the consistently and significantly increased risks of 
Alzheimer's disease that are associated with vascular risk factors, unless we 
severely misciassifY large numbers of patients. Several prospective studies are 
now available that show that vascular risk factors increase the long-term risk of 
dementia, which suggests that although mechanism 3 may playa role, this most 
likely is a limited one. To fmther unravel possible mechanisms I, 2 and 4 we 
need more specific disease markers, and repeated assessment of risk factors and 
outcome. 
Methodological considerations 
While epidemiological and other evidence is accumulating that vascular risk 
factors and indicators of vascular disease might be important in the cause and 
progression of dementia and Alzheimer's disease, some issues that need 
particular attention become apparent. 
First, the distinction between Alzheimer's disease with vascular pathology 
and vascular dementia is often very difficult and maybe even impossible. There 
is little agreement on what should be criteria for vascular dementia, and the 
criteria that are being used show bad reproducibility.28 Although the NINCDS-
ADRDA criteria for Alzheimer's disease are widely accepted and show good 
reproducibility,28 they still do not guarantee that the clinical syndrome of 
Alzheimer's disease refers to one clearly delineated disease entity. It may 
actually be a mixhlre of Alzheimer pathology and cerebrovascular pathology. 
Until we have better ways to distinguish between subtypes of dementia, it may 
be more infonnative to consider overall dementia and to distinguish according to 
aetiology, without the assumption that these subgroups indeed reflect clearly 
separable diagnostic entities. 
A second issue is the time of diagnosis in relation to neuronal damage. 
Alzheimer's disease may develop over a long period of time. At time of exposure 
assessment, Alzheimer pathology may have already started. Rather than shldying 
determinants of clinically overt dementia, we may want to investigate 
determinants of early markers of incipient dementia. Possible candidates are 
cerebral changes that we can detect with neuroimaging, in particular atrophy and 
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white matter lesions. To the extent that these are indeed early markers of 
incipient dementia, they may serve as a proxy measure. An approach that 
focuses on the detection of persons at risk for dementia in an early, and 
preferably pre symptomatic, stage would also make sense from a more clinical 
perspective where we want to prevent the development and progression of 
dementia. This also calls for identification of markers of early disease (e.g. brain 
atrophy, white matter changes, and serum levels of beta amyloid) and for 
investigation of determinants of those markers. 
A final issue is how to discern the time order of events. Neuronal damage that 
eventually leads to Alzheimer's disease may develop over a long period. Since 
vascular pathology may also develop over decades it can become difficult or 
even impossible to distinguish what is cause and what is consequence. Also, 
since most vascular risk factors are not stable over time, change in vascular risk 
factor level may be more important than actual level. To investigate these 
relations, we need long prospective follow-up studies. By now, several studies, 
including our own, have the necessmy data to address questions of sequence of 
events. The analysis of such complex datasets used to be extremely difficult, but 
has become much more feasible due to new methods for analysis of repeated 
measurements and imputation of missing values that have become available over 
the last years. 29,30 
Clinical relevance 
Research on vascular factors in the aetiology of dementia and Alzheimer's 
disease is fostered by the idea that this might offer clues for preventive 
intervention. Although observational epidemiological shldies are not specifically 
designed to give guidelines for clinical practice, we would like to consider if and 
how our findings can bear on current clinical practice. 
The shldies described in chapter 3 indicate that the relation between blood 
pressure and dementia is complicated and time-dependent. High blood pressure 
was associated with an increased risk of dcmentia. A decline in blood pressure 
was a risk factor for dementia independent of baseline blood pressure level. Use 
of blood pressure lowering medication was associated with a lower risk of 
dementia two years later, whereas persons who used blood pressure lowering 
medication but also had a low blood pressure were at increased risk of dementia. 
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From this study and also from othcrs wc might conclude that hypeltension 
contributes to thc development of Alzheimer's disease 2, 3, 31 and thus that 
treatment of hypertension would reduce the incidence of dementia, However, 
since it is possible that a decline in blood pressure also causes or contributes to 
dcmentia, it is too early to recommcnd blood prcssure lowering as a means to 
prevent demcntia, 
Light-to-moderate alcohol intake was associated with a lowcr risk of 
dementia. Because of underreporting of alcohol intake in epidemiological 
studies it is difficult to set scnsible liInits for levels beneficial to the development 
of dementia. Moreover, we have to be cautious recommending taking alcoholic 
beverages in order to prevent dementia, because it has bccn shown that in a large 
population, any increase in alcohol consumption is associated with a 
proportionate increase in heavy drinking.32 
Our findings suggest that atherosclerosis is not only associated with a small 
subgroup of vascular dementia, but also with Alzheimer's disease. Screening for 
and treatment of risk factors for atherosclerosis may not only lead to a lower risk 
of cardiovascular disease but may also contribute to a lower risk of dementia. 
Future research 
We have tricd to further quantifY the role of vascular factors in the aetiology of 
dementia and Alzheimer's disease. 
We studied blood prcssure level in relation to dementia. However, blood 
pressure measured in late life may not reflect blood pressurc lcvels earlier in life. 
A more direct measure of lifc time cumulative hypeltensive damage, in 
particular to thc cerebrovascular small vessels, is needed to further elucidate the 
role of hypeltension in the aetiology of dementia and in pmticular Alzheimer's 
disease. The distinct typc of changes that occur in retinal arterioles during 
different phases of hypeltensive disease may provide such a measure. 33 Another 
approach to establish a causal relationship between hypeltension and dementia is 
to perform a double blind randomised trial on the effects of trcatment of 
hypeltension, Recently, the Syst-Eur trial showed that treatment of isolated 
systolic hypeltension possibly reduced the risk of Alzheimer's disease.31 
However, the primmy hypothesis in this trial was that a reduction in blood 
pressure would protect against vascular dementia. As placebo controlled trials in 
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persons fulfilling established criteria for treatment are not possible on ethical 
grounds and considerable lowering of the blood pressure might be harmful, the 
only option would be to perfonll a placebo controlled trial in persons with mild 
hypertension. 
Our studies indicated the potential role of cerebral hypoperfusion in the 
pathogenesis of dementia. Since the research on cerebral blood flow velocity and 
cerebral vasomotor reactivity was done cross-sectionally and comprised a 
limited number of dementia cases, the objective of future research should be to 
assess the role of cerebral blood flow in a prospective study with long follow-up. 
Techniques that are used to measure cerebral blood flow include Transcranial 
Doppler, structural and functional magnetic resonance imaging (MRI), single 
photon emission computed tomography (SPECT), and positron emission 
tomography (PET). However, Transcranial Doppler is probably the only 
technique that is suitable for examining persons in large population based 
shldies. 
Alzheimer pathology starts probably long before it causes clinical symptoms. 
Future research should aim at identification of very early stages of the disease. 
Possible markers of preclinical stages of disease include levels of beta amyloid 
or tau in plasma, stl11Chlral brain changes as white matter lesions and 
hippocampal and medial temporal lobe atrophy, and functional brain markers34-
36 To the extent that these will be found to indeed reflect incipient Alzheimer's 
disease, they may serve as more specific outcome measures in etiologic shldies. 
Findings from shldies on the combined effect of apolipoprotein-E and 
vascular factors suggest that genetic factors may interact with vascular factors in 
the development of dementia. Future research should further investigate the 
interaction of genetic factors with vascular factors (e.g. angiotensin I converting 
enzyme, IL-l A polymorphism).37-39 
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7.1 
Summary 
This thesis describes our research to further explore the role of vascular 
pathology in dementia and Alzheimer's disease and to identify possible 
underlying mechanisms. All studies were performed within the Rotterdam 
Study, a population-based prospective cohort study on frequency and 
determinants of disease among elderly persons. At baseline (1990-1993) 7,983 
inhabitants of Ommoord, a suburb of Rotterdam, the Netherlands, who were 55 
years of age or older, participated. Follow-up examinations were done in 1993-
1994 and 1997-1999. In addition, study participants are continuously being 
followed for the development of cognitive problems or dementia through an 
extensive monitoring system through medical records from general practitioners 
and the Regional Institute for Outpatient Mental Health Care (RIAGG). At 
baseline, 482 persons of the 7,528 that were cogllitively evaluated were 
diagnosed with dementia. 
Study pmticipants without dementia at baseline (7,046) were followed for on 
average 5.7 years (chapter 2.1). During that period 395 persons developed 
dementia. Alzheimer's disease was the most frequent subtype of dementia (293 
cases, 74%). Vascular dementia was diagnosed in 57 participants (14%). The 
rate at which new dementia develops (incidence) is expressed in cases per 1,000 
persons-years of follow-up. The overall incidence rate was 9.8 per 1,000 person-
years for all types of dementia, 7.2 per 1,000 person-years for Alzheimer's 
disease, and 1.5 per 1,000 person-years for vascular dementia. The incidence 
rate ranged from 0.4 per 1,000 person-years at age 55-59 years to 74.1 per 1,000 
person-years at age 95 years and older. Up to age 90 years there was no 
difference in dementia incidence between men and women. However, after that 
age dementia incidence declined in men but not in women. Across all age groups 
women were more likely to develop Alzheimer's disease, whereas men were 
more often diagnosed with vascular dementia. 
In chapter 3, we studied the relation between blood pressure and the risk of 
dementia, and dementia subtypes. We first studied the short -tenn (on average 2 
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years) relation between blood pressure level, blood pressure lowering 
medication, and dementia (chapter 3.1). In persons younger than 85 years of age 
blood pressure was not associated with risk of dementia, whereas in older 
persons increasing levels of blood pressure were associated with lower risks of 
dementia. This decreased risk among hypertensive elderly was entirely due to a 
strong inverse association in persons using blood pressure lowering medication. 
Use of blood pressure lowering medication was associated with a lower risk of 
vascular dementia (chapter 3.3). We then studied the relation between blood 
pressure level and risk of dementia over a longer period after the baseline 
assessment (on average 6 years). Higher baseline blood pressure levels were 
associated with an increased risk of dcmentia, in particular for persons younger 
than 75 years of age. This association was observed for vascular dementia as 
well as for Alzheimer's disease. Finally, we examined the relation between 
change in blood pressure and subsequent risk of dementia. We found that a 
decline in blood pressure was associated with an increased risk of Alzheimer's 
disease and vascular dementia in the years thereafter, irrespective of baseline 
blood pressure level (chapter 3.2). 
In chapter 4 we investigated the relation between indicators of vascular 
disease and occurrence of dementia and cognitive impairment. In chapter 4.1 
we investigated cerebrovascular function as assessed by means of Transcranial 
Doppler in relation to cognitive dysfimction and dementia. We measured 
cerebral blood flow velocity, a measure of perfilsion of the brain, and 
cerebrovascular CO2 reactivity, which reflects the ability of small cerebral 
arteries to dilate under the influence of certain stimuli in order to increase 
cerebral blood flow in case of increased demands. Atherosclerosis may disturb 
the integrity and function of the arterial wall and thereby its capacity to dilate on 
these stimuli. Our data suggested that cerebral blood flow velocity and 
cerebrovascular CO2 reactivity were decreased in persons with dementia and 
were ah'eady lower in persons with low cognitive performance. In chaptcr 4.2 
we reported our findings on indicators of atherosclerosis and risk of dementia. 
Plaques in the carotid arteries and thickening of the carotid artelY vessel wall 
were significantly associated with an increased risk of dementia and Alzheimer's 
disease. The risk of dementia increased with the amount of atherosclerosis. In 
chaptcr 4.3 we evaluated the role of alcohol consumption on the risk of 
dementia and dementia subtypes. Persons who drank one to three glasses of 
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alcohol pcr day had a 40 pcrccnt lowcr risk of dementia as compared to persons 
who never drank alcohol. The risk of vascular dementia was even 70 pcrcent 
lower. The effects were similar for drinking wine, beer, liquor or fortified wine-
typcs. The association between alcohol and dementia was modified by the 
Apolipoprotcin-E gcnotype in that the risk reduction with moderate alcohol 
intake was stronger in persons with an Apolipoprotein E4 allele. 
In chapter 5 we described the natural progression of disease among 
Alzhcimer's disease patients. We constructcd a function based on age, gender, 
education and Apolipoprotein-E genotype to predict the rate of cognitive dccline 
in Alzheimer patients. In addition, we developed functions to estimate a 
demented individual's risk of institutionalisation and death based on age, gender 
and cognitive performance. We considered prevalent and incident dementia 
patients separately. Prevalent patients showed a slower decline in cognitive 
function than incident patients. For prevalent and incident Alzheimer's disease 
patients high age and low cognitive performance were the strongest prcdictors 
for institutionalisation and death. 
In chapter 6 wc discussed the results of the studies presented in this thesis. 
The possible underlying mechanisms were addressed in the light of our fmdings 
and some directions for future research were given. Various vascular factors, of 
which some are modifiable, were significantly associated with the risk of 
dementia. Most vascular factors were also related to Alzheimer's disease. 
Whcther the association reflects co-incidence of Alzheimer's disease and 
vascular disease, a causal relation between vascular factors and Alzheimer's 
disease, or a biologic interaction bctwecn vascular factors and Alzheimer 
pathology remains unclear. 
Future research should aim at further elucidating possible mechanisms in the 
relation between vascular factors and dementia. Emphasis should be on studying 
determinants of early, preferably preclinical, disease. 
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7.2 
Samenvatting 
Dit proefsehrift bcsehrijft onderzoek naar de rol van vaseulaire factoren in het 
ontstaan van dementie en de ziekte van Alzheimer. Het onderzoek werd verrieht 
als onderdeel van het Erasmus Rotterdam Gezondheid en Oudcren (ERGO) 
onderzoek, een prospcetief bevolkingsonderzoek naar frcquentie en oorzaken 
van ehronische zielcten bij ouderen. Het ERGO onderzoek begon in 1990-1993 
met 7983 inwoners van Ommoord, ccn wijk van Rotterdam, die op dat moment 
55 jaar en ouder waren. III 1993-1994 en in 1997-1999 werd iedereen opnicuw 
onderzocht. Vanaf het begin van de studie zijn deehlemers gevolgd en is 
bijgehouden of mensen eognitieve problemen of dementie kregen. Dit vond 
onder andere plaats door koppeling van geautomatiseerde huisartsenbestanden 
aan het ERGO databestand en door regelmatigc eontrole van medische dossiers 
bij het RIAGG. Aan het begin van het onderzoek werd bij 482 van de 7528 
personcn dic olldcrzoeht werden op hunmentale funeties dcmentie vastgesteld. 
Deelnemers zonder dementie syndroom aan het begin van de studic (7046), 
werden gemiddeld 5,7 jaar gevolgd (hoofdstuk 2.1). Tijdens deze periodc 
ontwikkelden 395 personen een dementie syndroom; bij 293 personen was 
daarbij sprake van de ziekte van Alzheimer (74%) en bij 57 personen werd een 
vaseulaire dementie vastgeste1d (14%). De ineidentie, of weI hct aantal nieuwc 
zielctegevallen dat zich in de loop van een tijdspcriode voordoet, voor mensen 
van 55 jaar en ouder was 9,8 pCI' 1000 persoonsjaren voor dementic; 7,2 per 
1,000 persoonsjarcn voor de ziekte van Alzheimer en 1,5 per 1,000 
persoonsjaren Vaal' vaseulaire dementie. De ineidentie nam toe van 0,4 per 1000 
persoonsjaren vaal' mensen van 55-60 jaar tot 74.1 per 1000 persoonsjaren vaal' 
mensen van 95 jaar en ouder. De incidentie van dementic was tot 90 jarige 
leeftijd gelijk voor mannen en vrouwen; boven die leeftijd leek de ineidentie 
vaal' mannen af te nemen, tcrwijl deze voor vrouwen bleef toenemcn. Over aile 
leeftijdsgrocpcn heen werd bij vrouwen vaker dan bij manllen de ziekte van 
Alzheimer vastgesteld en bij mannen vaker dan bij vrouwen vaseulaire dementie 
geeonstateerd. 
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Hoofdstuk 3 beschrijft ons onderzoek naar de relatie tussen de bloeddruk en de 
kans op dementie en subtypen van dementie. Eerst beshldeerden we de korte 
tel1l1.ijn (gemiddeld 2 jaar) invloed van de hoogte van de bloeddruk en 
bloeddrukverlagende medicijnen op het ontstaan van dementie (hoofdstuk 3.1). 
Voor personen jonger dan 85 jaar was de hoogte van de bloeddruk niet 
gerelateerd aan de kans op dementie. Bij oudere personell daarentegen was een 
hogere bloeddruk gerelateerd aan een lagere kans op dementie, echter aileen bij 
mensen die bloeddruk verlagende medicijnen gebruikten. Het gebruik van 
bloeddruk verlagende medicijnen bleek geassocicerd met een lagere kans op het 
krijgen van demelltie, en met name op het krijgen van vasculaire dcmentie 
(hoofdstuk 3.3). Vervolgens onderzochten we welke invloed de hoogte van de 
bloeddruk had op het ontstaan van demcntic na een langere periode (gemiddeld 
6 jaar). Een hoger bloeddruk niveau bleek gerelateerd aan een hogerc kans op 
dementie, met name bij mensen jonger dan 75 jaar. Dezelfde relaties werden 
gevonden voor de zickte van Alzheimer en voor vasculaire dementie (hoofdstuk 
3.2). 
In hoofdstuk 4 onderzochten wc of afwijkingen aan de vaatwand gerelateerd 
waren aan het optreden van dementie en cognilieve problemen. In hoofdstuk 4.1 
bestudeerden we met behulp van een Transcranielc Doppler functionele 
afwijkingell aan de hersenvaten in relatie tot dementie en cognitieve problemcn. 
Daarbij registreerden we de doorbloedingsnelheid van de herscncn cn de reactie 
van de hcrsenvaten op toedicning van kooldioxide. Dit laatste geeft het 
vermogen van de kleine hersenvaten weer om nit te zetten onder invloed van 
bepaalde prikkels en zodoende de doorbloeding van de hersenen te vergroten. 
Onder andere aderverkalking kan de functie van de vaatwand, en daarmec het 
vennogen om nit te zetten als reactie op prikkels, aantasten. Vil dit onderzoek 
bleek dat zowel de doorbloedillgsnellleid als het vennogen om nit te zetten 
verminderd waren bij demente personen en bij personen met cogllilieve 
problemcll. In hoofdstuk 4.2 rapporteerden we onze bevindingen over 
slagaderverkalking en de kans op dementie. Verkalking- en verdikking van de 
halsslagaderwand waren gerelateerd aan het ontstaan van dementie en de ziekte 
van Alzheimer. De kans op dementie nam toe met toenemende verkalking van 
de halsslagader. In hoofdstuk 4.3 bestudeerden we de invloed van het drillken 
van alcohol op het krijgcn van dementie, de ziekre van Alzheimer en vasculaire 
dementie. Personen die I tot 3 glazen alcohol per dag dronken hadden 40% 
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mindel' kans op het krijgen van dementie dan personen die geen alcohol dronken. 
De kans op vascnlaire dementie was zelfs 70 procent lager. Het maakte niet uit 
of de alcohol afkomstig was uit bier, wijn, sterke drank of sheny. De associatie 
van alcohol met dementie werd beYnvloed door het ApolipoproteYne-E genotype. 
Dragers van het Apolipoprote'ine 84 allel hadden meer baat bij het drinken van 
alcohol dan niet-dragers van het 84 aile!. 
In hoofdstnk 5 beschreven we de pragnose van de ziekte van Alzheimer. Om 
achtel1litgang in cognitieve functies te kunnen voorspellen maakten we een 
predictieve fnnctie gebaseerd op gegevens over leeftijd, geslacht, opleiding en 
Apolipoprote'ine-E genotype. Dam'naast ontwikkelden we fnneties waarmee voor 
een demente persoon de kans geschat kan worden om te worden 
geinstitntionaliseerd of te overlijden, nit gegevens over leeftijd, geslaeht en 
cognitief functioneren. We maakten aparte funeties voor mensen die de ziekte al 
langeI' had den (prevalente cases) en personen waarbij de ziekte net ontstaan was 
(ineidente patienten). Personen met allanger bestaande dementie veltoonden een 
langzamere achteruitgang in cognitief functioneren dan personen die de ziekte 
pas hadden gekregen. Hoge leeftijd en lage cognitieve functie waren in beidc 
graepen de sterkste voorspellers voor institntionalisering en dood gaan. 
In hoofdstuk 6 zijn de bevindingen van het onderzoek, beschreven in dit 
proefschrift, besproken. Mechanismen die onze bevindingen mogelijk kUllllen 
verklaren werden genoemd en we deden aanbevelingen voor toekomstig 
onderzoek. Diverse risicofactoren voor hart- en vaatziekten, waarvan sommigen 
be'invloedbaar, bleken geassocieerd met de kans op dementie. Dc meeste van 
deze risicofactoren waren ook geassoeieerd met de kans op de ziekte van 
Alzheimer. Of deze associatie veroorzaakt wordt doordat de ziekte van 
Alzheimer en vasculaire factoren onafhankelijk van elkaar vaak voorkomen, 
door een direct oorzakelijk verband tnssen de ziekte van Alzheimer en vasculaire 
faetoren of door biologische interaetie van vasculaire factoren met Alzheimer 
pathologie blijft onduidelijk. Toekomstig onderzoek zal gericht moeten worden 
op het ophelderen van mechanismen die ten grands lag kunnen liggen aan deze 
rclatie. Daarbij dient de nadruk te liggen op het bestuderen van determinanten 
van zo vroeg 11l0gelijke stadia van preklinische dementie. 
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